<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id>
<journal-title-group>
<journal-title>PLOS Computational Biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1006664</article-id>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-18-01501</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cell processes</subject><subj-group><subject>Cell cycle and cell division</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Blood cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune cells</subject><subj-group><subject>White blood cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Bone marrow cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Cellular types</subject><subj-group><subject>Animal cells</subject><subj-group><subject>Stem cells</subject><subj-group><subject>Hematopoietic stem cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject><subj-group><subject>Point mutation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological processes</subject><subj-group><subject>Hematopoiesis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological processes</subject><subj-group><subject>Hematopoiesis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Women's health</subject><subj-group><subject>Maternal health</subject><subj-group><subject>Birth</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Women's health</subject><subj-group><subject>Obstetrics and gynecology</subject><subj-group><subject>Birth</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Carcinogenesis</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Mutation, drift and selection in single-driver hematologic malignancy: Example of secondary myelodysplastic syndrome following treatment of inherited neutropenia</article-title>
<alt-title alt-title-type="running-head">Evolutionary model of MDS</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wojdyla</surname>
<given-names>Tomasz</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9140-9765</contrib-id>
<name name-style="western">
<surname>Mehta</surname>
<given-names>Hrishikesh</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Glaubach</surname>
<given-names>Taly</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Bertolusso</surname>
<given-names>Roberto</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Iwanaszko</surname>
<given-names>Marta</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Braun</surname>
<given-names>Rosemary</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Corey</surname>
<given-names>Seth J.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="fn" rid="econtrib001"><sup>‡</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Kimmel</surname>
<given-names>Marek</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
<xref ref-type="aff" rid="aff009"><sup>9</sup></xref>
<xref ref-type="fn" rid="econtrib001"><sup>‡</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Systems Engineering Group, Silesian University of Technology, Gliwice, Poland</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Pediatrics, Cleveland Clinic, Cleveland, OH, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Cancer Biology, Cleveland Clinic, Cleveland, OH, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Clinical Pediatrics, Division of Hospital Medicine, Stony Brook Children's Hospital, Stony Brook, New York</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Department of Statistics, Rice University, Houston, TX, United States of America</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Department of Preventive Medicine–Division of Biostatistics, Northwestern University, Chicago, IL United States of America</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Department of Engineering Sciences and Applied Mathematics, Northwestern University, Evanston, IL United States of America</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, United States of America</addr-line></aff>
<aff id="aff009"><label>9</label> <addr-line>Department of Bioengineering, Rice University, Houston, TX, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Gallo</surname>
<given-names>James</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University at Buffalo - The State University of New York, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="other" id="econtrib001">
<p><sup>‡</sup> These authors are joint senior authors on this work.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">kimmel@stat.rice.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>7</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>1</month>
<year>2019</year>
</pub-date>
<volume>15</volume>
<issue>1</issue>
<elocation-id>e1006664</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Wojdyla et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pcbi.1006664"/>
<abstract>
<p>Cancer development is driven by series of events involving mutations, which may become fixed in a tumor via genetic drift and selection. This process usually includes a limited number of driver (advantageous) mutations and a greater number of passenger (neutral or mildly deleterious) mutations. We focus on a real-world leukemia model evolving on the background of a germline mutation. Severe congenital neutropenia (SCN) evolves to secondary myelodysplastic syndrome (sMDS) and/or secondary acute myeloid leukemia (sAML) in 30–40%. The majority of SCN cases are due to a germline <italic>ELANE</italic> mutation. Acquired mutations in <italic>CSF3R</italic> occur in &gt;70% sMDS/sAML associated with SCN. Hypotheses underlying our model are: an <italic>ELANE</italic> mutation causes SCN; <italic>CSF3R</italic> mutations occur spontaneously at a low rate; in fetal life, hematopoietic stem and progenitor cells expands quickly, resulting in a high probability of several tens to several hundreds of cells with <italic>CSF3R</italic> truncation mutations; therapeutic granulocyte colony-stimulating factor (G-CSF) administration early in life exerts a strong selective pressure, providing mutants with a growth advantage. Applying population genetics theory, we propose a novel two-phase model of disease development from SCN to sMDS. In Phase 1, hematopoietic tissues expand and produce tens to hundreds of stem cells with the <italic>CSF3R</italic> truncation mutation. Phase 2 occurs postnatally through adult stages with bone marrow production of granulocyte precursors and positive selection of mutants due to chronic G-CSF therapy to reverse the severe neutropenia. We predict the existence of the pool of cells with the mutated truncated receptor <italic>before</italic> G-CSF treatment begins. The model does not require increase in mutation rate under G-CSF treatment and agrees with age distribution of sMDS onset and clinical sequencing data.</p>
</abstract>
<abstract abstract-type="summary">
<title>Author summary</title>
<p>Cancer develops by multistep acquisition of mutations in a progenitor cell and its daughter cells. Severe congenital neutropenia (SCN) manifests itself through an inability to produce enough granulocytes to prevent infections. SCN commonly results from a germline <italic>ELANE</italic> mutation. Large doses of the blood growth factor granulocyte colony-stimulating factor (G-CSF) rescue granulocyte production. However, SCN frequently transforms to a myeloid malignancy, commonly associated with a somatic mutation in <italic>CSF3R</italic>, the gene encoding the G-CSF Receptor. We built a mathematical model of evolution for <italic>CSF3R</italic> mutation starting with bone marrow expansion at the fetal development stage and continuing with postnatal competition between normal and malignant bone marrow cells. We employ tools of probability theory such as multitype branching processes and Moran models modified to account for expansion of hematopoiesis during human development. With realistic coefficients, we obtain agreement with the age range at which malignancy arises in patients. In addition, our model predicts the existence of a pool of cells with mutated <italic>CSF3R</italic> before G-CSF treatment begins. Our findings may be clinically applied to intervene more effectively and selectively in SCN patients.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>R01HL128173</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Corey</surname>
<given-names>Seth J.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004281</institution-id>
<institution>Narodowe Centrum Nauki</institution>
</institution-wrap>
</funding-source>
<award-id>DEC-2012/04/A/ST7/00353</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Kimmel</surname>
<given-names>Marek</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>American Society of Hematology</institution>
</funding-source>
<award-id>RO1CA108992,</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Corey</surname>
<given-names>Seth J.</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>TW and MK were supported by the grant DEC-2012/04/A/ST7/00353 from the National Science Center (Poland). MK, MI, RB, HM, and SJC were supported by NIH R01HL128173. HM was supported by a Leukemia Research Foundation award. TG was supported by an MDS International Foundation Young Investigator Award. SJC was supported by grants from the NIH RO1CA108992, American Society for Hematology Bridge Award, Leukemia and Lymphoma Translational Award, and the Department of Defense Bone Marrow Failure IDEA grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="2"/>
<page-count count="22"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>PLOS Publication Stage</meta-name>
<meta-value>vor-update-to-uncorrected-proof</meta-value>
</custom-meta>
<custom-meta>
<meta-name>Publication Update</meta-name>
<meta-value>2019-01-17</meta-value>
</custom-meta>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Cancer development is driven by series of mutational events, which may become fixed in a hematologic or non-hematologic tumor via genetic drift. This process usually includes a limited number of driver (advantageous) mutations, and a greater number of passenger (neutral or mildly deleterious) mutations. Driver mutations for several hundred different cancers have been identified by sequencing and functional assays. The relationship between driver and passenger mutations has been investigated using mathematical models representing carcinogenesis in terms of a “tug-of war” between the former and the latter [<xref ref-type="bibr" rid="pcbi.1006664.ref001">1</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref002">2</xref>]. Another related problem is whether carcinogenesis is driven by acquisition of single point mutations or by saltatory changes amounting to major genome rearrangement events [<xref ref-type="bibr" rid="pcbi.1006664.ref003">3</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref004">4</xref>]. Mathematical modeling of interactions among multiple drivers has been described by Nowak and Durrett and their colleagues [<xref ref-type="bibr" rid="pcbi.1006664.ref005">5</xref>–<xref ref-type="bibr" rid="pcbi.1006664.ref007">7</xref>]. These frequently involve branching processes and related mathematical models [<xref ref-type="bibr" rid="pcbi.1006664.ref008">8</xref>]. Among stochastic models in hematology, an example is [<xref ref-type="bibr" rid="pcbi.1006664.ref009">9</xref>]. Hematopoiesis provide the best-characterized system for cell fate decision-making in both health and disease [<xref ref-type="bibr" rid="pcbi.1006664.ref010">10</xref>], as well as connections between stimuli such as inflammation and cancer [<xref ref-type="bibr" rid="pcbi.1006664.ref011">11</xref>].</p>
<p>Here, we model a disease evolving on the background of a germline mutation. The acquired driver mutation recurs during tissue expansion phase in fetal life and becomes selectively advantageous in early childhood, leading to development of malignancy. As a prominent example of such disease, we model the important hematologic disorder Severe Congenital Neutropenia (SCN), a monogenic inherited disorder, that acquires new mutations and evolves to secondary myelodysplastic syndrome (sMDS) or secondary acute myeloid leukemia (sAML). This model is similar to the “fish” graph of Tomasetti and Vogelstein [<xref ref-type="bibr" rid="pcbi.1006664.ref012">12</xref>]; however the latter is more comprehensive and involves multiple driver case. Here, we use tools of population genetics and population dynamics to model progression from SCN to sMDS and dissect the contributions of mutation, drift and selection at different stages of an individual’s life. More specifically, we consider:</p>
<list list-type="order">
<list-item><p>In an individual primed by an inherited genotype, the driver mutation occurs recurrently in the embryonic expansion stage, although these mutations do not necessarily confer selective advantage.</p></list-item>
<list-item><p>At birth, due to environmental and behavioral factors or treatment, the driver mutation acquires a selective advantage in a tissue or organ, while the driver mutation may or may not recur as frequently any more.</p></list-item>
<list-item><p>The mutant driver variant increases in frequency due to selection, and eventually it dominates the stem cells of the tissue or the organ, contributing to development of disease.</p></list-item>
</list>
<p>Accordingly, SCN is most commonly due to germline mutations in <italic>ELANE</italic>, which encodes the neutrophil elastase [<xref ref-type="bibr" rid="pcbi.1006664.ref013">13</xref>]. SCN is characterized by the near absence of circulating neutrophils, which renders the child, typically an infant, susceptible to recurrent life-threatening infections. The introduction in the 1990s of recombinant granulocyte colony-stimulating factor (G-CSF) to increase circulating neutrophils, markedly improved survival and quality of life for SCN patients [<xref ref-type="bibr" rid="pcbi.1006664.ref014">14</xref>].</p>
<p>SCN often transforms into sMDS or sAML [<xref ref-type="bibr" rid="pcbi.1006664.ref015">15</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref016">16</xref>]. Clinical studies have demonstrated a strong association between exposure to G-CSF and sMDS/AML [<xref ref-type="bibr" rid="pcbi.1006664.ref017">17</xref>–<xref ref-type="bibr" rid="pcbi.1006664.ref021">21</xref>]. Mutations in the distal domain of the Granulocyte Colony-Stimulating Factor Receptor (<italic>CSF3R</italic>) have been isolated from almost all SCN patients who developed sMDS/AML [<xref ref-type="bibr" rid="pcbi.1006664.ref022">22</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref023">23</xref>]. Clonal evolution over approximately 20 years was documented using next generation sequencing and quantification of <italic>CSF3R</italic> allele frequency variation in an SCN patient who developed sMDS/sAML [<xref ref-type="bibr" rid="pcbi.1006664.ref024">24</xref>]. Strikingly, out of four different mutations in <italic>CSF3R</italic>, one persisted into the leukemic clone but the other three were lost, supporting the assumption of different selective values in the presence of G-CSF that underlies our model. As clonal evolution is a central feature in cancer [<xref ref-type="bibr" rid="pcbi.1006664.ref025">25</xref>–<xref ref-type="bibr" rid="pcbi.1006664.ref028">28</xref>] and next generation sequencing has revealed complex genomic landscapes, SCN may provide a simpler real-world example to study cancer development.</p>
<p>Two opposing paradigms have been proposed for cell fate decision making in blood cells: stochastic hematopoiesis (based on variability observed in cultured bone marrow cells as first suggested by McCulloch and Till [<xref ref-type="bibr" rid="pcbi.1006664.ref029">29</xref>]) and deterministic, or instructive, hematopoiesis (growth factor-driven production of specific blood cell types) [<xref ref-type="bibr" rid="pcbi.1006664.ref030">30</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref031">31</xref>]. In spite of substantial experimental findings, particularly recent single-cell measurements [<xref ref-type="bibr" rid="pcbi.1006664.ref032">32</xref>], the two opposing theories await a grand synthesis. Disease-accompanying dynamics have been variously modeled over the years as deterministic or stochastic[<xref ref-type="bibr" rid="pcbi.1006664.ref010">10</xref>]. SCN may also provide a simpler real-world example to study cell fate determination.</p>
<p>Little is known about the molecular mechanism(s) by which SCN leads to myeloid malignancy and how important are the truncating mutations such as <italic>CSF3R D715</italic> in this process. Notwithstanding the exact molecular mechanism by which the <italic>CSF3R</italic> truncation mutants lead to sMDS/AML, two pivotal questions concerning the population dynamics and population genetics of the mutant clones are: (i) whether the <italic>CSF3R</italic> truncation mutants are present before application of G-CSF, and (ii) whether G-CSF administration increases mutation rate in hematopoietic stem cells with <italic>ELANE</italic> mutation. If the answer to the first question is affirmative, then the presence of a small subpopulation of <italic>CSF3R</italic> truncation mutants among infants with SCN might be of prognostic value and a preventive therapy might be sought. Concerning the second question, determination whether G-CSF is mutagenic or provides a selective pressure may influence the degree G-CSF therapy is conducted, e.g. should it be more or less aggressive.</p>
<p>To provide insight into the course of this disease and its clinical management, we propose a novel model of the emergence and fixation of <italic>CSF3R</italic> truncating mutations, which also follows the paradigm outlined earlier on. We note that the most common of these mutations associated with transition to sMDS is the <italic>CSF3R D715</italic>. However, at the resolution level of our model, we are not able to make more specific distinctions nor to consider coexistence or competition of more than one truncation mutant. The model assumes that the answer to question (i) is affirmative, but it is negative to question (ii). The model’s hypotheses are:</p>
<list list-type="order">
<list-item><p>An inherited mutation in <italic>ELANE</italic> causes SCN;</p></list-item>
<list-item><p><italic>ELANE</italic> mutations coexist with the non-mutated allele in an intracellular environment in which <italic>CSF3R</italic> truncating mutations occur spontaneously at a low rate;</p></list-item>
<list-item><p>During fetal life, the number of stem cells and committed cells expands quickly, which results in high probability of approximately <inline-formula id="pcbi.1006664.e001"><alternatives><graphic id="pcbi.1006664.e001g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e001" xlink:type="simple"/><mml:math display="inline" id="M1"><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> <italic>CSF3R</italic> truncation mutant cells; these would be of no consequence had their number not expanded further;</p></list-item>
<list-item><p>Administration of pharmacologic G-CSF early in life exerts selective pressure, providing <italic>CSF3R</italic> mutants with selective advantage. This assumption is supported by experiments, in which growth differential of wild-type and truncation mutant depends on the G-CSF concentration (<bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1</xref></bold>).</p></list-item>
</list>
<fig id="pcbi.1006664.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g001</object-id>
<label>Fig 1</label>
<caption>
<title/>
<p><bold>(A). Effect of CSF3R (wild type or D715) stimulation on cell cycle</bold>. Ba/F3 cells expressing either wild type (Type I, blue) or mutant (D715, red) CSF3R were stimulated with two different doses of G-CSF (50 ng/ml and 100 ng/ml) and were analyzed using flow cytometry to determine the effect of G-CSF dose on receptor subtype activation on cell cycle progression. The cells were treated as detailed in the <bold>Methods</bold>. Flow cytometry data for each time point were analyzed using FlowJo employing the built-in cell cycle module. The data are represented as percentage of G1/G0 cells obtained from the FlowJo analysis plotted against time. Following an initial transient, from the 1 hr time point the G1/G0 percentage differences between cells with the Type I and D715 receptors have been on the average equal to 6.05% for 100 ng of G-CSF and 4.28% for 50 ng of G-CSF, respectively.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.g001" xlink:type="simple"/>
</fig>
<list list-type="order">
<list-item><p>Onset of sMDS is equivalent with replacement of normal hematopoietic bone marrow by mutant hematopoietic stem cells, their progeny, and release of factors that suppress normal hematopoiesis. At the level of resolution of our model, we are not able to make more specific distinctions.</p></list-item>
</list>
<p><bold>(B) Effect of CSF3R (wild type vs. D715) on cell proliferation</bold>. Ba/F3 cells expressing either wild type (Type I) or mutant (D715) <italic>CSF3R</italic> were treated with increasing doses of recombinant human G-CSF (ng/ml) and proliferation was measured by the MTT assay performed in triplicates in a 96 well plate. The data are raw absorbance values at 600 nm and represent the three replicates plotted against increasing dose of G-CSF, fitted using least squares by Hill-type curves (Type I, blue, D715 red). For details of experimental procedures see the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. Fitting and statistical procedures are explained in the <bold>Methods</bold>.</p>
<p>We show that hypotheses 2 and 3 are needed, by first building a proof-of-principle simple Moran process (a stochastic model used in population genetics) with no expansion, which fits the data only if it is started by a cell population including <inline-formula id="pcbi.1006664.e002"><alternatives><graphic id="pcbi.1006664.e002g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e002" xlink:type="simple"/><mml:math display="inline" id="M2"><mml:mo>⁓</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> cells expressing a <italic>CSF3R</italic> truncation mutation. Then we show that this number of <italic>CSF3R</italic> truncation mutant cells can be produced in the late fetal period expansion of hematopoiesis in bone marrow. Existence of the pool of <italic>CSF3R</italic> truncation mutant cells before exposure to G-CSF can be discovered only by deep targeted sequencing. Then we follow up with a full-fledged comprehensive model, which accounts for the important detail of time change of the size of the hematopoietic system, but which confirms the conclusions of the proof-of-principle model.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003">
<title>Measuring the selective advantage of D 715 mutant cells</title>
<sec id="sec004">
<title>Experiment</title>
<p>As shown in <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1A</xref></bold>, the fraction of Ba/F3 cells expressing either wild type (Type I, blue) or mutant (D715, red) CSF3R that reside in the G1/G0 phase has been measured, employing flow cytometry. Technical details are found in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. Briefly, following release from the starvation cell cycle arrest, cells were stimulated with two different doses of G-CSF (50 ng/ml and 100 ng/ml) and were analyzed using flow cytometry to determine the effect of G-CSF dose on receptor subtype activation in terms of cell cycle progression. Flow cytometry data for each time point were analyzed using FlowJo software [<xref ref-type="bibr" rid="pcbi.1006664.ref033">33</xref>] employing the built-in cell cycle module. The data are represented as percentage of G1/G0 cells obtained from the FlowJo analysis plotted against time. After an initial transient, from the 1 hr time point the G1/G0 percentage differences between cells with the Type I and D715 receptors have been on the average equal to 6.05% for 100 ng of G-CSF and 4.28% for 50 ng of G-CSF, respectively. The data points are derived from flow cytometry, and because it measures thousands of cells, statistical fluctuations play a minor role and therefore the differences are statistically “highly significant”.</p>
<p>G1/G0 cell fraction as a measure of selective advantage of cycling cells. We employ a simple cell cycle model to relate the G1/G0 cell fraction to the cell growth rate and selective advantage. Mathematical foundations can be found for example in ref. [<xref ref-type="bibr" rid="pcbi.1006664.ref034">34</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref035">35</xref>]. Briefly, suppose that the interdivision time <inline-formula id="pcbi.1006664.e003"><alternatives><graphic id="pcbi.1006664.e003g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e003" xlink:type="simple"/><mml:math display="inline" id="M3"><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula> of cell in a population is constant and that the residence time <inline-formula id="pcbi.1006664.e004"><alternatives><graphic id="pcbi.1006664.e004g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e004" xlink:type="simple"/><mml:math display="inline" id="M4"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> in the G1/G0 is also constant (relaxing these assumptions is possible, as implicit from [<xref ref-type="bibr" rid="pcbi.1006664.ref034">34</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref035">35</xref>], but it does not affect the first-order approximation we need here). Let us also suppose that the efficiency of divisions <inline-formula id="pcbi.1006664.e005"><alternatives><graphic id="pcbi.1006664.e005g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e005" xlink:type="simple"/><mml:math display="inline" id="M5"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula> (probability that a progeny cell enters the cell cycle) is constant. Under these hypotheses, the expected cell growth after initial transients becomes exponential with rate <inline-formula id="pcbi.1006664.e006"><alternatives><graphic id="pcbi.1006664.e006g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e006" xlink:type="simple"/><mml:math display="inline" id="M6"><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">ln</mml:mi></mml:mrow><mml:mo>⁡</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>2</mml:mn><mml:mi>α</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula>, i.e. the cell count at time <inline-formula id="pcbi.1006664.e007"><alternatives><graphic id="pcbi.1006664.e007g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e007" xlink:type="simple"/><mml:math display="inline" id="M7"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula> is equal to
<disp-formula id="pcbi.1006664.e008">
<alternatives>
<graphic id="pcbi.1006664.e008g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e008" xlink:type="simple"/>
<mml:math display="block" id="M8">
<mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>The fraction <inline-formula id="pcbi.1006664.e009"><alternatives><graphic id="pcbi.1006664.e009g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e009" xlink:type="simple"/><mml:math display="inline" id="M9"><mml:mi>φ</mml:mi></mml:math></alternatives></inline-formula> of cells in G1/G0, tends to the following value
<disp-formula id="pcbi.1006664.e010">
<alternatives>
<graphic id="pcbi.1006664.e010g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e010" xlink:type="simple"/>
<mml:math display="block" id="M10">
<mml:mrow><mml:mi>φ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>This latter expression can be solved for the ratio <inline-formula id="pcbi.1006664.e011"><alternatives><graphic id="pcbi.1006664.e011g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e011" xlink:type="simple"/><mml:math display="inline" id="M11"><mml:mi>ψ</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula>
<disp-formula id="pcbi.1006664.e012">
<alternatives>
<graphic id="pcbi.1006664.e012g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e012" xlink:type="simple"/>
<mml:math display="block" id="M12">
<mml:mrow><mml:mi>ψ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>φ</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>α</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>α</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>Suppose now that we consider another (“asterisked”) population of cycling cells, which has respective parameters denoted with superscript <inline-formula id="pcbi.1006664.e013"><alternatives><graphic id="pcbi.1006664.e013g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e013" xlink:type="simple"/><mml:math display="inline" id="M13"><mml:msup><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:math></alternatives></inline-formula>Let us also assume that the difference in cell division times between the two populations is due only to shortening of the G1/G0 phase
<disp-formula id="pcbi.1006664.e014">
<alternatives>
<graphic id="pcbi.1006664.e014g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e014" xlink:type="simple"/>
<mml:math display="block" id="M14">
<mml:mrow><mml:mi>T</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mi>T</mml:mi><mml:mn>1</mml:mn><mml:mo>*</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mo>Δ</mml:mo></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>Let us note that in the experiment described earlier on, we measure the ratios <inline-formula id="pcbi.1006664.e015"><alternatives><graphic id="pcbi.1006664.e015g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e015" xlink:type="simple"/><mml:math display="inline" id="M15"><mml:mi>φ</mml:mi></mml:math></alternatives></inline-formula> (G1/G0 fraction in Type I receptor cells) and <inline-formula id="pcbi.1006664.e016"><alternatives><graphic id="pcbi.1006664.e016g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e016" xlink:type="simple"/><mml:math display="inline" id="M16"><mml:msup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> (G1/G0 fraction in D 715 receptor cells). Following some algebra, we obtain an estimate of <inline-formula id="pcbi.1006664.e017"><alternatives><graphic id="pcbi.1006664.e017g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e017" xlink:type="simple"/><mml:math display="inline" id="M17"><mml:mi mathvariant="normal">Δ</mml:mi></mml:math></alternatives></inline-formula> in the terms of <inline-formula id="pcbi.1006664.e018"><alternatives><graphic id="pcbi.1006664.e018g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e018" xlink:type="simple"/><mml:math display="inline" id="M18"><mml:mi>φ</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e019"><alternatives><graphic id="pcbi.1006664.e019g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e019" xlink:type="simple"/><mml:math display="inline" id="M19"><mml:msup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> given we assume <inline-formula id="pcbi.1006664.e020"><alternatives><graphic id="pcbi.1006664.e020g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e020" xlink:type="simple"/><mml:math display="inline" id="M20"><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e021"><alternatives><graphic id="pcbi.1006664.e021g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e021" xlink:type="simple"/><mml:math display="inline" id="M21"><mml:mi>α</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e022"><alternatives><graphic id="pcbi.1006664.e022g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e022" xlink:type="simple"/><mml:math display="inline" id="M22"><mml:msup><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>
<disp-formula id="pcbi.1006664.e023">
<alternatives>
<graphic id="pcbi.1006664.e023g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e023" xlink:type="simple"/>
<mml:math display="block" id="M23">
<mml:mrow><mml:mi>Δ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>ψ</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>ψ</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>ψ</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:mrow></mml:mfrac><mml:mi>T</mml:mi></mml:mrow>
</mml:math>
</alternatives>
</disp-formula>
where <inline-formula id="pcbi.1006664.e024"><alternatives><graphic id="pcbi.1006664.e024g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e024" xlink:type="simple"/><mml:math display="inline" id="M24"><mml:mi>ψ</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e025"><alternatives><graphic id="pcbi.1006664.e025g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e025" xlink:type="simple"/><mml:math display="inline" id="M25"><mml:msup><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> have been already expressed in the terms of <inline-formula id="pcbi.1006664.e026"><alternatives><graphic id="pcbi.1006664.e026g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e026" xlink:type="simple"/><mml:math display="inline" id="M26"><mml:mi>φ</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e027"><alternatives><graphic id="pcbi.1006664.e027g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e027" xlink:type="simple"/><mml:math display="inline" id="M27"><mml:msup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>.</p>
<p>Selective coefficient in the Moran model is defined as <inline-formula id="pcbi.1006664.e028"><alternatives><graphic id="pcbi.1006664.e028g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e028" xlink:type="simple"/><mml:math display="inline" id="M28"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula>, where <inline-formula id="pcbi.1006664.e029"><alternatives><graphic id="pcbi.1006664.e029g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e029" xlink:type="simple"/><mml:math display="inline" id="M29"><mml:mi>r</mml:mi></mml:math></alternatives></inline-formula> is the ratio of probabilities that the replacent for a withdrawn (divided) self-renewing cell is a mutant (in this case an “asterisked” cell) and, respectively, wild-type. This interpretation is consistent with the confined environment of the bone marrow, in which on the average one progeny cell dies or differentiates, leaving the self-renewing cell pool. This leads to expression
<disp-formula id="pcbi.1006664.e030">
<alternatives>
<graphic id="pcbi.1006664.e030g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e030" xlink:type="simple"/>
<mml:math display="block" id="M30">
<mml:mrow><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>λ</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>−</mml:mo><mml:mi>λ</mml:mi></mml:mrow><mml:mi>λ</mml:mi></mml:mfrac></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>This interpretation allows understanding the bounds on the selection coefficient provided by the experiment. We accepted <inline-formula id="pcbi.1006664.e031"><alternatives><graphic id="pcbi.1006664.e031g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e031" xlink:type="simple"/><mml:math display="inline" id="M31"><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:mn>4</mml:mn></mml:math></alternatives></inline-formula> days, and we may start from assuming <inline-formula id="pcbi.1006664.e032"><alternatives><graphic id="pcbi.1006664.e032g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e032" xlink:type="simple"/><mml:math display="inline" id="M32"><mml:mi>α</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula> (perfect division efficiency). Suppose that in approximate agreement with the experiment, we consider <inline-formula id="pcbi.1006664.e033"><alternatives><graphic id="pcbi.1006664.e033g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e033" xlink:type="simple"/><mml:math display="inline" id="M33"><mml:mi>φ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e034"><alternatives><graphic id="pcbi.1006664.e034g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e034" xlink:type="simple"/><mml:math display="inline" id="M34"><mml:msup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.66</mml:mn></mml:math></alternatives></inline-formula>, which leads to <inline-formula id="pcbi.1006664.e035"><alternatives><graphic id="pcbi.1006664.e035g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e035" xlink:type="simple"/><mml:math display="inline" id="M35"><mml:mi>ψ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.621</mml:mn></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e036"><alternatives><graphic id="pcbi.1006664.e036g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e036" xlink:type="simple"/><mml:math display="inline" id="M36"><mml:msup><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.567</mml:mn></mml:math></alternatives></inline-formula>, and to <inline-formula id="pcbi.1006664.e037"><alternatives><graphic id="pcbi.1006664.e037g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e037" xlink:type="simple"/><mml:math display="inline" id="M37"><mml:mo>Δ</mml:mo><mml:mo>=</mml:mo><mml:mn>0.503</mml:mn></mml:math></alternatives></inline-formula>. In turn, this provides <inline-formula id="pcbi.1006664.e038"><alternatives><graphic id="pcbi.1006664.e038g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e038" xlink:type="simple"/><mml:math display="inline" id="M38"><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mn>0.173</mml:mn><mml:msup><mml:mrow><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e039"><alternatives><graphic id="pcbi.1006664.e039g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e039" xlink:type="simple"/><mml:math display="inline" id="M39"><mml:msup><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.198</mml:mn><mml:msup><mml:mrow><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> which leads to <inline-formula id="pcbi.1006664.e040"><alternatives><graphic id="pcbi.1006664.e040g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e040" xlink:type="simple"/><mml:math display="inline" id="M40"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>0.144</mml:mn></mml:math></alternatives></inline-formula>. Lowering equally the division efficiencies of both cell types changes the selection coefficient only slightly. However, if the “asterisked” (mutant) efficiency is lowered to <inline-formula id="pcbi.1006664.e041"><alternatives><graphic id="pcbi.1006664.e041g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e041" xlink:type="simple"/><mml:math display="inline" id="M41"><mml:msup><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.93</mml:mn></mml:math></alternatives></inline-formula>, the selective advantage of faster proliferating cells shrinks to almost 0. Consistently with this, we use the range of <inline-formula id="pcbi.1006664.e042"><alternatives><graphic id="pcbi.1006664.e042g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e042" xlink:type="simple"/><mml:math display="inline" id="M42"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>-values from 0.005 to 0.1 (<xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref>) and from 0.008 to 0.02 (<bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref></bold>), which stay below the upper bound provided by <inline-formula id="pcbi.1006664.e043"><alternatives><graphic id="pcbi.1006664.e043g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e043" xlink:type="simple"/><mml:math display="inline" id="M43"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>0.144</mml:mn></mml:math></alternatives></inline-formula>.</p>
<fig id="pcbi.1006664.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g002</object-id>
<label>Fig 2</label>
<caption>
<title/>
<p><bold>(A)</bold> Age at which the d715 mutants replace the normal cells in the CMP compartment, as predicted by the modified Moran model with varying cell population size, for a range of mutation rate and selection coefficient values. <bold>(B)</bold> Selection coefficient values corresponding to the ages at replacement of 4 years old (solid line), 13 years old (dashed line), and 22 years old (dotted line) for a range of mutation rates values. <bold>(C)</bold> Mutant cell count at age of 1 year for a range of mutation rate values.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.g002" xlink:type="simple"/>
</fig>
<table-wrap id="pcbi.1006664.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.t001</object-id>
<label>Table 1</label> <caption><title>Results of the computations of the expected time to fixation.</title></caption>
<alternatives>
<graphic id="pcbi.1006664.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" style="border-bottom:thick"><inline-formula id="pcbi.1006664.e044"><alternatives><graphic id="pcbi.1006664.e044g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e044" xlink:type="simple"/><mml:math display="inline" id="M44"><mml:mi mathvariant="bold-italic">s</mml:mi></mml:math></alternatives></inline-formula></th>
<th align="center" style="border-bottom:thick"><inline-formula id="pcbi.1006664.e045"><alternatives><graphic id="pcbi.1006664.e045g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e045" xlink:type="simple"/><mml:math display="inline" id="M45"><mml:mi mathvariant="bold-italic">i</mml:mi></mml:math></alternatives></inline-formula></th>
<th align="center" style="border-bottom:thick"><inline-formula id="pcbi.1006664.e046"><alternatives><graphic id="pcbi.1006664.e046g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e046" xlink:type="simple"/><mml:math display="inline" id="M46"><mml:mi mathvariant="bold-italic">μ</mml:mi></mml:math></alternatives></inline-formula><break/>(cell division<sup>-1</sup>)</th>
<th align="center" style="border-bottom:thick"><inline-formula id="pcbi.1006664.e047"><alternatives><graphic id="pcbi.1006664.e047g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e047" xlink:type="simple"/><mml:math display="inline" id="M47"><mml:mi mathvariant="bold-italic">E</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">N</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:math></alternatives></inline-formula><break/>(yr.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">0.005</td>
<td align="center">240</td>
<td align="center">2.01×10<sup>−08</sup></td>
<td align="center">90.57</td>
</tr>
<tr>
<td align="center">0.01</td>
<td align="center">120</td>
<td align="center">1.00×10<sup>−08</sup></td>
<td align="center">46.05</td>
</tr>
<tr>
<td align="center">0.02</td>
<td align="center">60</td>
<td align="center">4.99×10<sup>−09</sup></td>
<td align="center">23.41</td>
</tr>
<tr>
<td align="center">0.03</td>
<td align="center">40</td>
<td align="center">3.31×10<sup>−09</sup></td>
<td align="center">15.75</td>
</tr>
<tr>
<td align="center">0.04</td>
<td align="center">29</td>
<td align="center">2.47×10<sup>−09</sup></td>
<td align="center">11.90</td>
</tr>
<tr>
<td align="center">0.05</td>
<td align="center">23</td>
<td align="center">1.97×10<sup>−09</sup></td>
<td align="center">9.57</td>
</tr>
<tr>
<td align="center">0.1</td>
<td align="center">11</td>
<td align="center">9.57×10<sup>−10</sup></td>
<td align="center">4.86</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Results of the computations of the expected time to fixation of a <italic>CSF3R</italic> truncation mutation with probability of fixation kept at <inline-formula id="pcbi.1006664.e048"><alternatives><graphic id="pcbi.1006664.e048g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e048" xlink:type="simple"/><mml:math display="inline" id="M48"><mml:mi>P</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula>, assuming the Moran process with directional selection. Notation: <inline-formula id="pcbi.1006664.e049"><alternatives><graphic id="pcbi.1006664.e049g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e049" xlink:type="simple"/><mml:math display="inline" id="M49"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, selection coefficient; <inline-formula id="pcbi.1006664.e050"><alternatives><graphic id="pcbi.1006664.e050g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e050" xlink:type="simple"/><mml:math display="inline" id="M50"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula>, mutant count at birth; <inline-formula id="pcbi.1006664.e051"><alternatives><graphic id="pcbi.1006664.e051g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e051" xlink:type="simple"/><mml:math display="inline" id="M51"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>, mutation rate (cell division<sup>-1</sup>). <inline-formula id="pcbi.1006664.e052"><alternatives><graphic id="pcbi.1006664.e052g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e052" xlink:type="simple"/><mml:math display="inline" id="M52"><mml:mi>E</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:math></alternatives></inline-formula> is the age at fixation of the <italic>CSF3R</italic> truncation mutant (yr). For detailed hypotheses and derivations, see the present section.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec005">
<title>Effect of CSF3R (wild type vs. D715) on cell proliferation</title>
<p>Ba/F3 cells expressing either wild type (Type I) or mutant (D715) <italic>CSF3R</italic> were treated with increasing doses of G-CSF (ng/ml) and proliferation was measured using the MTT assay performed in triplicates in a 96 well plate. Full account of experimental procedures is found in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. The data are raw absorbance values at 600 nm and represent the three replicates plotted against increasing dose of G-CSF.</p>
<p>Concerning recalculation from the pharmacological dose to serum concentration of the G-CSF, ref.[<xref ref-type="bibr" rid="pcbi.1006664.ref036">36</xref>] is providing relevant information. In this publication, see their <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1</xref></bold>, therapeutic doses from <inline-formula id="pcbi.1006664.e053"><alternatives><graphic id="pcbi.1006664.e053g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e053" xlink:type="simple"/><mml:math display="inline" id="M53"><mml:mn>5</mml:mn><mml:mo>–</mml:mo><mml:mn>15</mml:mn><mml:mspace width="0.25em"/><mml:mo>μ</mml:mo><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:math></alternatives></inline-formula> body weight resulted in serum concentrations of the order from <inline-formula id="pcbi.1006664.e054"><alternatives><graphic id="pcbi.1006664.e054g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e054" xlink:type="simple"/><mml:math display="inline" id="M54"><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mn>100</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula>, with a maximum for the lowest dose of <inline-formula id="pcbi.1006664.e055"><alternatives><graphic id="pcbi.1006664.e055g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e055" xlink:type="simple"/><mml:math display="inline" id="M55"><mml:mn>5</mml:mn><mml:mspace width="0.25em"/><mml:mo>μ</mml:mo><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:math></alternatives></inline-formula> reached after 4 hours and equal to over <inline-formula id="pcbi.1006664.e056"><alternatives><graphic id="pcbi.1006664.e056g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e056" xlink:type="simple"/><mml:math display="inline" id="M56"><mml:mn>10</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula>, and remaining over <inline-formula id="pcbi.1006664.e057"><alternatives><graphic id="pcbi.1006664.e057g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e057" xlink:type="simple"/><mml:math display="inline" id="M57"><mml:mn>1</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula> for 10 days.</p>
<p>To better understand the data, we performed parametric least-square fitting of the Type 1 and D715 data using Hill-like sigmoid curves, which results in clarified visualization of trends with the two curves crossing approximately at G-CSF concentration of <inline-formula id="pcbi.1006664.e058"><alternatives><graphic id="pcbi.1006664.e058g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e058" xlink:type="simple"/><mml:math display="inline" id="M58"><mml:mn>0.1</mml:mn><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:math></alternatives></inline-formula>. Hill equation is a prototypical sigmoidal curve widely used in systems biology [<xref ref-type="bibr" rid="pcbi.1006664.ref037">37</xref>]. It has the form
<disp-formula id="pcbi.1006664.e059">
<alternatives>
<graphic id="pcbi.1006664.e059g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e059" xlink:type="simple"/>
<mml:math display="block" id="M59">
<mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>ln</mml:mtext><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>ln</mml:mtext><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mi>n</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>The best least-square fit to the data (separately for Type I and D715 data). Values of estimated coefficients: Common for Type I and D715, <inline-formula id="pcbi.1006664.e060"><alternatives><graphic id="pcbi.1006664.e060g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e060" xlink:type="simple"/><mml:math display="inline" id="M60"><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.349</mml:mn></mml:math></alternatives></inline-formula>; Type 1, <italic>a</italic> = 0.449, <italic>b</italic> = 20.802, <italic>c</italic> = -23.309, <italic>n</italic> = 11.149; D715, <italic>a</italic> = 0.479, <italic>b</italic> = 21.075, <italic>c</italic> = -23.278, <italic>n</italic> = 28.255.</p>
<p>In addition, we carried out rigorous testing using one-sided Wilcoxon two-sample rank test of the difference between the Type 1 and D715 data points separately for concentrations <inline-formula id="pcbi.1006664.e061"><alternatives><graphic id="pcbi.1006664.e061g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e061" xlink:type="simple"/><mml:math display="inline" id="M61"><mml:mo>&gt;</mml:mo><mml:mn>0.1</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula> (resulting in highly significant difference at <inline-formula id="pcbi.1006664.e062"><alternatives><graphic id="pcbi.1006664.e062g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e062" xlink:type="simple"/><mml:math display="inline" id="M62"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0034</mml:mn></mml:math></alternatives></inline-formula>), and for concentrations <inline-formula id="pcbi.1006664.e063"><alternatives><graphic id="pcbi.1006664.e063g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e063" xlink:type="simple"/><mml:math display="inline" id="M63"><mml:mo>≤</mml:mo><mml:mn>0.1</mml:mn><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula> (resulting in borderline significant difference in opposite direction at <inline-formula id="pcbi.1006664.e064"><alternatives><graphic id="pcbi.1006664.e064g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e064" xlink:type="simple"/><mml:math display="inline" id="M64"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.089</mml:mn></mml:math></alternatives></inline-formula>). This testing justifies the assertion of higher growth rate of D715 cell in the range of G-CSF concentrations above <inline-formula id="pcbi.1006664.e065"><alternatives><graphic id="pcbi.1006664.e065g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e065" xlink:type="simple"/><mml:math display="inline" id="M65"><mml:mn>0.1</mml:mn><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula>.</p>
</sec>
</sec>
<sec id="sec006">
<title>Proof-of-principle model</title>
<sec id="sec007">
<title>Moran process with directional selection</title>
<p>For a simplified proof-of-principle model of competition between mutant and wild type cells in adult bone marrow, we use the standard Moran process with selection [<xref ref-type="bibr" rid="pcbi.1006664.ref038">38</xref>]. In this process (<bold><xref ref-type="fig" rid="pcbi.1006664.g003">Fig 3</xref></bold>), the population of granulocyte precursors is assumed to be constant, with the proportion of mutants varying in time, and time running in discrete units (such as days or cell-division times). We consider a population of <inline-formula id="pcbi.1006664.e066"><alternatives><graphic id="pcbi.1006664.e066g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e066" xlink:type="simple"/><mml:math display="inline" id="M66"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> biological cells, which at time 0 contains <inline-formula id="pcbi.1006664.e067"><alternatives><graphic id="pcbi.1006664.e067g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e067" xlink:type="simple"/><mml:math display="inline" id="M67"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> mutant cells. The mutant has a selective advantage defined as the relative fitness <inline-formula id="pcbi.1006664.e068"><alternatives><graphic id="pcbi.1006664.e068g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e068" xlink:type="simple"/><mml:math display="inline" id="M68"><mml:mi>r</mml:mi></mml:math></alternatives></inline-formula>, which is frequently expressed as <inline-formula id="pcbi.1006664.e069"><alternatives><graphic id="pcbi.1006664.e069g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e069" xlink:type="simple"/><mml:math display="inline" id="M69"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, where <inline-formula id="pcbi.1006664.e070"><alternatives><graphic id="pcbi.1006664.e070g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e070" xlink:type="simple"/><mml:math display="inline" id="M70"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> is called the selection coefficient. For an advantageous mutant, <inline-formula id="pcbi.1006664.e071"><alternatives><graphic id="pcbi.1006664.e071g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e071" xlink:type="simple"/><mml:math display="inline" id="M71"><mml:mi>r</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula>, or <inline-formula id="pcbi.1006664.e072"><alternatives><graphic id="pcbi.1006664.e072g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e072" xlink:type="simple"/><mml:math display="inline" id="M72"><mml:mi>s</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math></alternatives></inline-formula>. Further details are found in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p>
<fig id="pcbi.1006664.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Moran Process with discrete time and directional selection.</title>
<p>One of the <inline-formula id="pcbi.1006664.e073"><alternatives><graphic id="pcbi.1006664.e073g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e073" xlink:type="simple"/><mml:math display="inline" id="M73"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> cells (<inline-formula id="pcbi.1006664.e074"><alternatives><graphic id="pcbi.1006664.e074g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e074" xlink:type="simple"/><mml:math display="inline" id="M74"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> mutants, in orange, and <inline-formula id="pcbi.1006664.e075"><alternatives><graphic id="pcbi.1006664.e075g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e075" xlink:type="simple"/><mml:math display="inline" id="M75"><mml:mi>N</mml:mi><mml:mo>–</mml:mo><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> wildtype, in green), present at time <inline-formula id="pcbi.1006664.e076"><alternatives><graphic id="pcbi.1006664.e076g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e076" xlink:type="simple"/><mml:math display="inline" id="M76"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula>, dies (no preference for type). Its replacement at time <inline-formula id="pcbi.1006664.e077"><alternatives><graphic id="pcbi.1006664.e077g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e077" xlink:type="simple"/><mml:math display="inline" id="M77"><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula> is selected from all cells present at <inline-formula id="pcbi.1006664.e078"><alternatives><graphic id="pcbi.1006664.e078g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e078" xlink:type="simple"/><mml:math display="inline" id="M78"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula>, with odds (relative fitness) <italic>r</italic> in favor of the mutant. Relative fitness is frequently expressed as <inline-formula id="pcbi.1006664.e079"><alternatives><graphic id="pcbi.1006664.e079g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e079" xlink:type="simple"/><mml:math display="inline" id="M79"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, where <inline-formula id="pcbi.1006664.e080"><alternatives><graphic id="pcbi.1006664.e080g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e080" xlink:type="simple"/><mml:math display="inline" id="M80"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> is called the selection coefficient. For an advantageous mutant, <inline-formula id="pcbi.1006664.e081"><alternatives><graphic id="pcbi.1006664.e081g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e081" xlink:type="simple"/><mml:math display="inline" id="M81"><mml:mi>r</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula>, or <inline-formula id="pcbi.1006664.e082"><alternatives><graphic id="pcbi.1006664.e082g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e082" xlink:type="simple"/><mml:math display="inline" id="M82"><mml:mi>s</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math></alternatives></inline-formula>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec008">
<title>Selective advantage in cycling cells</title>
<p>CSF3R is a member of the hematopoietin/cytokine receptor family and functions as a homodimer. The cytoplasmic region consists of a proximal domain essential for proliferation and a distal domain critical for differentiation. Acquired CSF3R mutations have been observed to cluster between nucleotides 2384 to 2522 (residues 715 to 750), resulting in the loss of the distal domain [<xref ref-type="bibr" rid="pcbi.1006664.ref023">23</xref>]. Epidemiological studies demonstrated that the risk of sMDS/AML increased with the dose of G-CSF [<xref ref-type="bibr" rid="pcbi.1006664.ref016">16</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref039">39</xref>].</p>
<p>Mutant clones may divide more frequently and/or be less apoptotic. In the simplest case of no cell death, selective advantage can be related to shortening of the interdivision times in mutant cells, relative to normal cells. A proxy for shorter interdivision time is a lower proportion of cells in the G1 phase, as this phase is usually most variable. <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1A</xref></bold> presents a summary of the dynamics of cell cycle distribution of Ba/F3 cells expressing either the full-length wild type CSF3R or the CSF3R D715 mutant following their release from a starvation block. The fraction of cells in G1 in D715 mutants is lower by about 0.05 compared to that in the wild type CSF3R expressing cells, which translates into a growth rate advantage of the CSF3R D715 mutant. The difference is highly statistically significant, as flow cytometry measures thousands of cells per condition.</p>
<p>As an independent check, <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1B</xref></bold> shows a direct comparison of growth curves of Ba/F3 cells expressing either the full-length CSF3R or the truncated CSF3R D715. The dose dependence shows that mutants have a selective advantage over a range of high G-CSF concentrations, whereas for low (normal) concentrations, they are at best neutral or possibly disadvantageous. Relevant laboratory techniques are found in <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. Similar results were found depending on the particular CSF3R cytoplasmic mutant [<xref ref-type="bibr" rid="pcbi.1006664.ref040">40</xref>].</p>
</sec>
<sec id="sec009">
<title>CSF3R truncation mutations at the fetal-life expansion phase of bone marrow</title>
<p>Hematopoiesis in the human fetus moves from the liver into bone marrow about 90 days before the end of the pregnancy [<xref ref-type="bibr" rid="pcbi.1006664.ref041">41</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref042">42</xref>]. The requirement of more than one mutant cell present at time <italic>t</italic> = 0 of the Moran process can be satisfied as follows. Suppose that <italic>CSF3R</italic> truncation mutations occur during the embryonic bone marrow expansion stage. In this time interval, because of the rapid expansion on the bone marrow, cell proliferation and mutation can be described using the time-continuous Markov branching process model [<xref ref-type="bibr" rid="pcbi.1006664.ref008">8</xref>], originally developed by Coldman and Goldie in a different context [<xref ref-type="bibr" rid="pcbi.1006664.ref043">43</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref044">44</xref>]. The assumptions are as follows (<bold><xref ref-type="fig" rid="pcbi.1006664.g004">Fig 4</xref></bold>):</p>
<fig id="pcbi.1006664.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g004</object-id>
<label>Fig 4</label>
<caption>
<title>The branching process of cell proliferation with irreversible mutation.</title>
<p>Briefly, the cancer cell population is initiated by a single “wild type” (WT) cell, denoted as “0”. At each division, with probability <inline-formula id="pcbi.1006664.e083"><alternatives><graphic id="pcbi.1006664.e083g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e083" xlink:type="simple"/><mml:math display="inline" id="M83"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>, one of the WT progeny cells mutates. Mutants, denoted as “1” produce a pair of mutant progeny. Mutants have the same distribution of the interdivision time as the WT cells.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.g004" xlink:type="simple"/>
</fig>
<list list-type="order">
<list-item><p>The stem cell population (here, pooled Hematopoietic Stem Cells or HSC, and Common Myeloid Progenitors or CMP) is initiated by a small number <inline-formula id="pcbi.1006664.e084"><alternatives><graphic id="pcbi.1006664.e084g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e084" xlink:type="simple"/><mml:math display="inline" id="M84"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> of “wild type” (WT) cell that already acquired the <italic>ELANE</italic> mutation.</p></list-item>
<list-item><p>Interdivision time of WT cells is a random variable from an exponential distribution with parameter <inline-formula id="pcbi.1006664.e085"><alternatives><graphic id="pcbi.1006664.e085g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e085" xlink:type="simple"/><mml:math display="inline" id="M85"><mml:mi>λ</mml:mi></mml:math></alternatives></inline-formula>. Accordingly, mean interdivision time of WT cells is equal to <inline-formula id="pcbi.1006664.e086"><alternatives><graphic id="pcbi.1006664.e086g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e086" xlink:type="simple"/><mml:math display="inline" id="M86"><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>λ</mml:mi></mml:math></alternatives></inline-formula>.</p></list-item>
<list-item><p>At each division of a WT cell, with probability <inline-formula id="pcbi.1006664.e087"><alternatives><graphic id="pcbi.1006664.e087g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e087" xlink:type="simple"/><mml:math display="inline" id="M87"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>, one of the progeny cells acquires the <italic>CSF3R D715</italic> mutation. <italic>CSF3R</italic> truncation mutants always produce <italic>CSF3R</italic> truncation mutants when dividing.</p></list-item>
<list-item><p>At the expansion phase, mutants are assumed selectively neutral (have the same parameter <inline-formula id="pcbi.1006664.e088"><alternatives><graphic id="pcbi.1006664.e088g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e088" xlink:type="simple"/><mml:math display="inline" id="M88"><mml:mi>λ</mml:mi></mml:math></alternatives></inline-formula> as WT cells).</p></list-item>
</list>
<p>Mathematical details are found in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p>
</sec>
</sec>
<sec id="sec010">
<title>Comprehensive model of fixation of CSF3R truncation mutants</title>
<sec id="sec011">
<title>Modeling the age-dependent changes of sizes of the bone marrow cell compartments</title>
<p>For more precise simulations, we build a model of dynamics of the hematopoietic stem cells (HSC) these latter more properly defined as HSC and long term culture-initiating cells (LTC-IC) [<xref ref-type="bibr" rid="pcbi.1006664.ref045">45</xref>], and of the common myeloid progenitors (CMP), which give rise to neutrophils and/or monocytes. The model schematic is depicted in <bold><xref ref-type="fig" rid="pcbi.1006664.g005">Fig 5</xref></bold>. Dynamics of these cell populations are represented in the compartmental model by a system of three differential equations following the model of Arino and Kimmel [<xref ref-type="bibr" rid="pcbi.1006664.ref046">46</xref>]. The equations of the model are explained in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> and in the legends to <bold>Figs <xref ref-type="fig" rid="pcbi.1006664.g005">5</xref> </bold>and <bold><xref ref-type="fig" rid="pcbi.1006664.g006">6</xref>.</bold></p>
<fig id="pcbi.1006664.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Deterministic model of age-related dynamics of pluripotent and committed cells and granulocytes.</title>
<p><inline-formula id="pcbi.1006664.e089"><alternatives><graphic id="pcbi.1006664.e089g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e089" xlink:type="simple"/><mml:math display="inline" id="M89"><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1006664.e090"><alternatives><graphic id="pcbi.1006664.e090g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e090" xlink:type="simple"/><mml:math display="inline" id="M90"><mml:mi>C</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, and <inline-formula id="pcbi.1006664.e091"><alternatives><graphic id="pcbi.1006664.e091g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e091" xlink:type="simple"/><mml:math display="inline" id="M91"><mml:mi>G</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> are the numbers of pluripotent cells (HSC compartment), committed cells (CMP compartment), and peripheral granulocytes at time <inline-formula id="pcbi.1006664.e092"><alternatives><graphic id="pcbi.1006664.e092g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e092" xlink:type="simple"/><mml:math display="inline" id="M92"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula>, respectively; <inline-formula id="pcbi.1006664.e093"><alternatives><graphic id="pcbi.1006664.e093g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e093" xlink:type="simple"/><mml:math display="inline" id="M93"><mml:mi>m</mml:mi></mml:math></alternatives></inline-formula> is the ratio of the committed cells in the hematopoietic cell lineage associated with the granulocyte line (assumed to be <inline-formula id="pcbi.1006664.e094"><alternatives><graphic id="pcbi.1006664.e094g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e094" xlink:type="simple"/><mml:math display="inline" id="M94"><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mo>)</mml:mo><mml:mo>;</mml:mo><mml:mi>a</mml:mi></mml:math></alternatives></inline-formula>and <inline-formula id="pcbi.1006664.e095"><alternatives><graphic id="pcbi.1006664.e095g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e095" xlink:type="simple"/><mml:math display="inline" id="M95"><mml:mi>c</mml:mi></mml:math></alternatives></inline-formula> are the proliferation rate and self-renewal probability of the <inline-formula id="pcbi.1006664.e096"><alternatives><graphic id="pcbi.1006664.e096g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e096" xlink:type="simple"/><mml:math display="inline" id="M96"><mml:mi>P</mml:mi></mml:math></alternatives></inline-formula> cells; and, similarly, <inline-formula id="pcbi.1006664.e097"><alternatives><graphic id="pcbi.1006664.e097g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e097" xlink:type="simple"/><mml:math display="inline" id="M97"><mml:mi>b</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e098"><alternatives><graphic id="pcbi.1006664.e098g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e098" xlink:type="simple"/><mml:math display="inline" id="M98"><mml:mi>d</mml:mi></mml:math></alternatives></inline-formula> are the proliferation rate and self-renewal probability of the <inline-formula id="pcbi.1006664.e099"><alternatives><graphic id="pcbi.1006664.e099g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e099" xlink:type="simple"/><mml:math display="inline" id="M99"><mml:mi>C</mml:mi></mml:math></alternatives></inline-formula> cells. <inline-formula id="pcbi.1006664.e100"><alternatives><graphic id="pcbi.1006664.e100g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e100" xlink:type="simple"/><mml:math display="inline" id="M100"><mml:mi>E</mml:mi><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> denotes expected interdivision time of a cell.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.g005" xlink:type="simple"/>
</fig>
<fig id="pcbi.1006664.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Estimated dynamics of human hematopoiesis in the bone marrow, starting from its onset in the final weeks of fetal life.</title>
<p>(For additional details see the twin sections titled <italic>Estimates of the parameters of the model of age-dependent dynamics of the granulocyte arm of the hematopoietic system</italic>, in the Results and in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>). (A) Counts of the HSCs (<inline-formula id="pcbi.1006664.e101"><alternatives><graphic id="pcbi.1006664.e101g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e101" xlink:type="simple"/><mml:math display="inline" id="M101"><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>) and CMPs (<inline-formula id="pcbi.1006664.e102"><alternatives><graphic id="pcbi.1006664.e102g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e102" xlink:type="simple"/><mml:math display="inline" id="M102"><mml:mi>C</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>), and the rate of granulocyte production per day (<inline-formula id="pcbi.1006664.e103"><alternatives><graphic id="pcbi.1006664.e103g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e103" xlink:type="simple"/><mml:math display="inline" id="M103"><mml:mi>β</mml:mi><mml:mi>G</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>), as a function of time (individual’s age), calculated for human body weight following the Theron’s formula. (B) Time (individual’s age) dependent parameters of the mathematical model of the human hematopoietic system: expected time (days) between HSC divisions <inline-formula id="pcbi.1006664.e104"><alternatives><graphic id="pcbi.1006664.e104g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e104" xlink:type="simple"/><mml:math display="inline" id="M104"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>a</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, expected time (days) between CMP divisions <inline-formula id="pcbi.1006664.e105"><alternatives><graphic id="pcbi.1006664.e105g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e105" xlink:type="simple"/><mml:math display="inline" id="M105"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>b</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, maturation probability of the HSC <inline-formula id="pcbi.1006664.e106"><alternatives><graphic id="pcbi.1006664.e106g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e106" xlink:type="simple"/><mml:math display="inline" id="M106"><mml:mi>c</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, and differentiation probability of the CMP, <inline-formula id="pcbi.1006664.e107"><alternatives><graphic id="pcbi.1006664.e107g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e107" xlink:type="simple"/><mml:math display="inline" id="M107"><mml:mi>d</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>. Ratio of the committed cells in the hematopoietic cell lineage associated with the granulocyte lineage is assumed equal to <inline-formula id="pcbi.1006664.e108"><alternatives><graphic id="pcbi.1006664.e108g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e108" xlink:type="simple"/><mml:math display="inline" id="M108"><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:math></alternatives></inline-formula> for all ages. Please note the log-log scale of the graphs.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.g006" xlink:type="simple"/>
</fig>
<p>Our model is consistent with the lifetime changes in the bone marrow volume and the HSC interdivision times [<xref ref-type="bibr" rid="pcbi.1006664.ref047">47</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref048">48</xref>], distinguishes between the periods before and after birth, and accounts for the body mass and HSC proliferation changes during childhood and adulthood. This requires that some of the model parameters change with time <inline-formula id="pcbi.1006664.e109"><alternatives><graphic id="pcbi.1006664.e109g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e109" xlink:type="simple"/><mml:math display="inline" id="M109"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula> (individual’s age). We found that it is sufficient to vary (i) the mean interdivision time of the HSC equal to <inline-formula id="pcbi.1006664.e110"><alternatives><graphic id="pcbi.1006664.e110g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e110" xlink:type="simple"/><mml:math display="inline" id="M110"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>a</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, (ii) the maturation probability of the HSC equal to <italic><inline-formula id="pcbi.1006664.e111"><alternatives><graphic id="pcbi.1006664.e111g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e111" xlink:type="simple"/><mml:math display="inline" id="M111"><mml:mi>c</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula></italic>, and (iii) the differentiation probability of the CMP equal to <italic><inline-formula id="pcbi.1006664.e112"><alternatives><graphic id="pcbi.1006664.e112g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e112" xlink:type="simple"/><mml:math display="inline" id="M112"><mml:mi>d</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula></italic>. See <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> for explanation of mathematical symbols. The time (age) patterns of these and other coefficients that fit the data in refs. [<xref ref-type="bibr" rid="pcbi.1006664.ref047">47</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref048">48</xref>], are depicted in <bold><xref ref-type="fig" rid="pcbi.1006664.g006">Fig 6B</xref></bold>.</p>
<p>The model accommodates two apparently contradictory observations in the data viz. that (i) the interdivision times of the HSC dramatically increase over the lifetime, and (ii) the granulocyte volume remains proportional to the body weight [<xref ref-type="bibr" rid="pcbi.1006664.ref047">47</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref048">48</xref>]. Surprisingly, this can be achieved by relatively small changes in the cell maturation and differentiation coefficients. In the real-life system, this is accomplished by nonlinear regulatory feedbacks, with possible configurations similar as in ref. [<xref ref-type="bibr" rid="pcbi.1006664.ref045">45</xref>]. However, for our purposes, it is sufficient to assume that differentiation coefficients <inline-formula id="pcbi.1006664.e113"><alternatives><graphic id="pcbi.1006664.e113g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e113" xlink:type="simple"/><mml:math display="inline" id="M113"><mml:mi>c</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e114"><alternatives><graphic id="pcbi.1006664.e114g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e114" xlink:type="simple"/><mml:math display="inline" id="M114"><mml:mi>d</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> vary with time (<bold><xref ref-type="fig" rid="pcbi.1006664.g006">Fig 6B</xref></bold>). Mathematical details and parameter estimates are found in the corresponding sections of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p>
</sec>
<sec id="sec012">
<title>Model of expansion of the CSF3R truncation mutant in the bone marrow in the form of the Moran process with variable population size, directional selection, and recurrent mutation</title>
<p>In contrast to the standard Moran process, this model assumes that the population size (cell count) <italic>N(t)</italic> varies in time. The population consists of cells of two types: wild type (WT; cells that already acquired the <italic>ELANE</italic> mutation) and <italic>CSF3R</italic> truncation mutants (M). For the WT-cells and M-cells equally, life lengths depend on individual’s age. Upon death of a cell, another randomly chosen cell proliferates. Selective advantage is represented by a bias in choice of proliferating cell (as in the standard Moran model. WT-cell may irreversibly mutate into a M-cell at rate <inline-formula id="pcbi.1006664.e115"><alternatives><graphic id="pcbi.1006664.e115g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e115" xlink:type="simple"/><mml:math display="inline" id="M115"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>. Mathematical details are found in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p>
<p>Technically, the model is limited to the CMP compartment of the bone marrow, since (1) cells in this compartment respond to G-CSF signaling as opposed to the HSC, which most likely do not, and (2) CMP compartment is much larger than the HSC one. Further stages of granulocyte precursors are assumed to only transmit the descendants of the mutated cells into peripheral blood and tissue and not to have even limited self-renewal properties. Before the GCS-F treatment is initiated, the mutants do not have selective advantage (i.e. <inline-formula id="pcbi.1006664.e116"><alternatives><graphic id="pcbi.1006664.e116g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e116" xlink:type="simple"/><mml:math display="inline" id="M116"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></alternatives></inline-formula>). Advantage appears at the time G-CSF treatment is administered, assumed to be six months after birth.</p>
</sec>
</sec>
</sec>
<sec id="sec013" sec-type="results">
<title>Results</title>
<sec id="sec014">
<title>Proof-of-principle model</title>
<sec id="sec015">
<title>Mutation rate, selection and age at sMDS onset in the proof-of-principle model</title>
<p>In this section, we consider a simple Moran model with the mutants being cells carrying the <italic>CSF3R</italic> truncation mutation. Since around 70% of sMDS associated with SCN carry this mutation, this means that fixation of the mutant (i.e., elimination of the wild-type <italic>CSF3R</italic> in the SCN population) occurs with probability 0.7 (ref. [<xref ref-type="bibr" rid="pcbi.1006664.ref023">23</xref>]). Assuming this and a given selection coefficient of the mutant over the wild type, we calculate (see <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>) the expected time to fixation and the required number of mutant cells at time 0 of the model (corresponding to birth of the individual). <bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref> </bold>presents results of the computations of the expected time to fixation of a <italic>CSF3R</italic> truncation mutation with probability of fixation kept at <inline-formula id="pcbi.1006664.e117"><alternatives><graphic id="pcbi.1006664.e117g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e117" xlink:type="simple"/><mml:math display="inline" id="M117"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mo>[</mml:mo><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>x</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>]</mml:mo><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula>, assuming the Moran process with directional selection. The parameter values are consistent with the adolescent phase values in the accurate model of bone marrow expansion, as well as with the experiment-based estimates of the selective advantage of cells harboring the <italic>CSF3R</italic> truncation mutation, as outlined further on.</p>
</sec>
<sec id="sec016">
<title>Determination of the expected time to fixation of the CSF3R truncation mutant and the required count of mutant-harboring cells at the end of fetal bone marrow expansion</title>
<p>Expected times to fixation of the <italic>CSF3R</italic> truncation mutant were computed by first solving Eq. (1) in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> to find the initial count <inline-formula id="pcbi.1006664.e118"><alternatives><graphic id="pcbi.1006664.e118g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e118" xlink:type="simple"/><mml:math display="inline" id="M118"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> of mutants required for <inline-formula id="pcbi.1006664.e119"><alternatives><graphic id="pcbi.1006664.e119g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e119" xlink:type="simple"/><mml:math display="inline" id="M119"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula>, given the summary number of HSC and CMP cells <inline-formula id="pcbi.1006664.e120"><alternatives><graphic id="pcbi.1006664.e120g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e120" xlink:type="simple"/><mml:math display="inline" id="M120"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> = 1.98×10<sup>8</sup> cells/kg ×75 kg (the average adult body weight) and selection coefficient <inline-formula id="pcbi.1006664.e121"><alternatives><graphic id="pcbi.1006664.e121g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e121" xlink:type="simple"/><mml:math display="inline" id="M121"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> varying in a wide range.</p>
<p>In mathematical terms, if the probability of fixation of the mutant is provided by the Eq. (1) in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>
<disp-formula id="pcbi.1006664.e122">
<alternatives>
<graphic id="pcbi.1006664.e122g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e122" xlink:type="simple"/>
<mml:math display="block" id="M122">
<mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>i</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow>
</mml:math>
</alternatives>
</disp-formula>
and for large <inline-formula id="pcbi.1006664.e123"><alternatives><graphic id="pcbi.1006664.e123g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e123" xlink:type="simple"/><mml:math display="inline" id="M123"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> and small <inline-formula id="pcbi.1006664.e124"><alternatives><graphic id="pcbi.1006664.e124g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e124" xlink:type="simple"/><mml:math display="inline" id="M124"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula>, the expected time to fixation (given that fixation occurs), is asymptotically equivalent to [<xref ref-type="bibr" rid="pcbi.1006664.ref038">38</xref>]
<disp-formula id="pcbi.1006664.e125">
<alternatives>
<graphic id="pcbi.1006664.e125g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e125" xlink:type="simple"/>
<mml:math display="block" id="M125">
<mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mtext>ln</mml:mtext><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mtext>ln</mml:mtext><mml:mi>i</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:mo>,</mml:mo></mml:mrow>
</mml:math>
</alternatives>
</disp-formula>
then we can solve the first of these two equations for <inline-formula id="pcbi.1006664.e126"><alternatives><graphic id="pcbi.1006664.e126g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e126" xlink:type="simple"/><mml:math display="inline" id="M126"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula>, assuming <inline-formula id="pcbi.1006664.e127"><alternatives><graphic id="pcbi.1006664.e127g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e127" xlink:type="simple"/><mml:math display="inline" id="M127"><mml:mi>P</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula> to obtain
<disp-formula id="pcbi.1006664.e128">
<alternatives>
<graphic id="pcbi.1006664.e128g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e128" xlink:type="simple"/>
<mml:math display="block" id="M128">
<mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mtext>log</mml:mtext></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>0.7</mml:mn><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
</disp-formula>
and then substitute this into the second equation to obtain
<disp-formula id="pcbi.1006664.e129">
<alternatives>
<graphic id="pcbi.1006664.e129g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e129" xlink:type="simple"/>
<mml:math display="block" id="M129">
<mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mtext>ln</mml:mtext><mml:mi>N</mml:mi><mml:mo>−</mml:mo><mml:mrow><mml:mtext>lnln</mml:mtext></mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mn>0.7</mml:mn><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mtext>lnln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mi>s</mml:mi></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>The latter has to be divided by the number of cell divisions per year (assumed to be equal to 90 as in Stiehl et al. [<xref ref-type="bibr" rid="pcbi.1006664.ref045">45</xref>]) to obtain time in years.</p>
<p>The resulting mutant cell counts and the expected age at fixation of the <italic>CSF3R</italic> truncation mutation are collected in the second and fourth column of <bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref></bold>, respectively.</p>
<p>For <inline-formula id="pcbi.1006664.e130"><alternatives><graphic id="pcbi.1006664.e130g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e130" xlink:type="simple"/><mml:math display="inline" id="M130"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> from the interval (0.02, 0.1), the estimates of the expected time to fixation of the mutant (time when only mutant allele remains) belong to the interval [4.86, 23.41] (yr), and are approximately consistent with the timing of the sMDS onset. From the European SCN Registry data, age at diagnosis of SCN with sMDS and <italic>CSF3R</italic> mutation is 13 ± 9 years. However, it is necessary that at the time G-CSF treatment begins, <inline-formula id="pcbi.1006664.e131"><alternatives><graphic id="pcbi.1006664.e131g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e131" xlink:type="simple"/><mml:math display="inline" id="M131"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> = 11–60 mutant cells are already present in the cell population (second column of <bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref></bold>).</p>
</sec>
<sec id="sec017">
<title>Determination of the mutation rates required to obtain the mutant cell counts at birth</title>
<p>To shed light at the possibility of this number of mutants being present approximately at the birth time, we solved Equation (3) in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> to obtain the estimates of mutation rate <inline-formula id="pcbi.1006664.e132"><alternatives><graphic id="pcbi.1006664.e132g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e132" xlink:type="simple"/><mml:math display="inline" id="M132"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula> which makes it possible, absent selection by G-CSF, to obtain the corresponding initial mutant count <inline-formula id="pcbi.1006664.e133"><alternatives><graphic id="pcbi.1006664.e133g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e133" xlink:type="simple"/><mml:math display="inline" id="M133"><mml:mi>i</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> in the range 11–60 in the fetal hematopoietic population of HSC and CMP expanding to the size of about <inline-formula id="pcbi.1006664.e134"><alternatives><graphic id="pcbi.1006664.e134g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e134" xlink:type="simple"/><mml:math display="inline" id="M134"><mml:mi>N</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> = 1.98×10<sup>8</sup> cells/kg ×5 kg (the approximate infant body weight).</p>
<p>Mathematically, under the branching process model (<bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>), we obtain the equations for the expected (average) number <inline-formula id="pcbi.1006664.e135"><alternatives><graphic id="pcbi.1006664.e135g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e135" xlink:type="simple"/><mml:math display="inline" id="M135"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> of normal and <inline-formula id="pcbi.1006664.e136"><alternatives><graphic id="pcbi.1006664.e136g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e136" xlink:type="simple"/><mml:math display="inline" id="M136"><mml:mi>i</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></alternatives></inline-formula>of mutant cells [<xref ref-type="bibr" rid="pcbi.1006664.ref008">8</xref>]
<disp-formula id="pcbi.1006664.e137">
<alternatives>
<graphic id="pcbi.1006664.e137g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e137" xlink:type="simple"/>
<mml:math display="block" id="M137">
<mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>λ</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>{</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>λ</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>λ</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>}</mml:mo></mml:mrow>
</mml:math>
</alternatives>
</disp-formula></p>
<p>Eliminating time from the relationship between <inline-formula id="pcbi.1006664.e138"><alternatives><graphic id="pcbi.1006664.e138g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e138" xlink:type="simple"/><mml:math display="inline" id="M138"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e139"><alternatives><graphic id="pcbi.1006664.e139g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e139" xlink:type="simple"/><mml:math display="inline" id="M139"><mml:mi>i</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></alternatives></inline-formula>, we obtain that the expected number of mutant cells is equal to
<disp-formula id="pcbi.1006664.e140">
<alternatives>
<graphic id="pcbi.1006664.e140g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e140" xlink:type="simple"/>
<mml:math display="block" id="M140">
<mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mn>0</mml:mn><mml:mi>μ</mml:mi></mml:msubsup><mml:mi>N</mml:mi><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:msup><mml:mspace width="0.25em"/><mml:mo>≅</mml:mo><mml:mspace width="0.25em"/><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:msup><mml:mspace width="0.25em"/><mml:mo>≅</mml:mo><mml:mspace width="0.25em"/><mml:mi>μ</mml:mi><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.25em"/><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow>
</mml:math>
</alternatives>
</disp-formula>
where <inline-formula id="pcbi.1006664.e141"><alternatives><graphic id="pcbi.1006664.e141g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e141" xlink:type="simple"/><mml:math display="inline" id="M141"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> (resp. <inline-formula id="pcbi.1006664.e142"><alternatives><graphic id="pcbi.1006664.e142g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e142" xlink:type="simple"/><mml:math display="inline" id="M142"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>) is the number of cells after (resp. before) expansion. The approximation on the right-hand side is valid for moderate <inline-formula id="pcbi.1006664.e143"><alternatives><graphic id="pcbi.1006664.e143g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e143" xlink:type="simple"/><mml:math display="inline" id="M143"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> and small <inline-formula id="pcbi.1006664.e144"><alternatives><graphic id="pcbi.1006664.e144g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e144" xlink:type="simple"/><mml:math display="inline" id="M144"><mml:mi>μ</mml:mi></mml:math></alternatives></inline-formula>. Inverting this expression, we obtain the mutation rates for a given expected number of mutant cells.</p>
<p>The resulting mutation rates per cell division, ranging from 9.57×10<sup>−10</sup> to 4.99×10<sup>−09</sup>, with cell cycle time of the CMP (which dominate in the pooled HSC and CMP population; see further on) assumed equal to 4 days (as in Stiehl et al. [<xref ref-type="bibr" rid="pcbi.1006664.ref045">45</xref>]), do not exceed the values considered normal for human cells (<bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref></bold>).</p>
<p>As for <bold><xref ref-type="table" rid="pcbi.1006664.t002">Table 2</xref></bold>, we select the mutation rates and expected times to fixation to be a subset of those in <bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref> </bold>and compare the respective selection coefficients stemming from the simplified model and the comprehensive model. A more complete review of possible parameter combination is possible using <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref> </bold>as a nomogram; see further on.</p>
<table-wrap id="pcbi.1006664.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.t002</object-id>
<label>Table 2</label> <caption><title>Comparison of estimates of selection coefficients needed for fixation of the <italic>CSF3R mutant</italic>.</title></caption>
<alternatives>
<graphic id="pcbi.1006664.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" style="border-bottom:thick">Age at <italic>CSF3R</italic> truncation<break/>fixation (yr)</th>
<th align="left" style="border-bottom:thick">Mutation rate <inline-formula id="pcbi.1006664.e145"><alternatives><graphic id="pcbi.1006664.e145g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e145" xlink:type="simple"/><mml:math display="inline" id="M145"><mml:mi mathvariant="bold-italic">μ</mml:mi></mml:math></alternatives></inline-formula><break/>(cell division<sup>-1</sup>)</th>
<th align="left" style="border-bottom:thick">Selection coefficient (<inline-formula id="pcbi.1006664.e146"><alternatives><graphic id="pcbi.1006664.e146g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e146" xlink:type="simple"/><mml:math display="inline" id="M146"><mml:mi mathvariant="bold-italic">s</mml:mi></mml:math></alternatives></inline-formula>), based on proof-of-principle model</th>
<th align="left" style="border-bottom:thick">Selection coefficient (<inline-formula id="pcbi.1006664.e147"><alternatives><graphic id="pcbi.1006664.e147g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e147" xlink:type="simple"/><mml:math display="inline" id="M147"><mml:mi mathvariant="bold-italic">s</mml:mi></mml:math></alternatives></inline-formula>), based on comprehensive model</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">4</td>
<td align="left">1 × 10<sup>−9</sup></td>
<td align="left">0.10</td>
<td align="left">0.054</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">2.5 × 10<sup>−9</sup></td>
<td align="left">0.04</td>
<td align="left">0.014</td>
</tr>
<tr>
<td align="left">22</td>
<td align="left">5 × 10<sup>−9</sup></td>
<td align="left">0.02</td>
<td align="left">0.008</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Comparison of estimates of selection coefficients (rounded) needed for fixation of the <italic>CSF3R</italic> truncation mutant at a given age, based on the proof-of-principle and comprehensive models, with the corresponding mutation rates (rounded) corresponding to simulations underlying estimates in <bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref></bold>.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec018">
<title>Comprehensive model of fixation of CSF3R truncation mutants</title>
<p>The results of the proof-of-principle modeling summarized in <bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref> </bold>suggest that it is feasible to build a more comprehensive model consistent with normal hematopoiesis as well as mutation and selection mechanisms modified by the age-dependent cellularity of the bone marrow and administration of pharmacological G-CSF.</p>
<sec id="sec019">
<title>Estimates of the parameters of the model of age-dependent dynamics of the granulocyte arm of the hematopoietic system</title>
<p>We assume that the total number of HSC, CMP, and granulocytes is proportional to body weight, which increases according to Theron's formula [<xref ref-type="bibr" rid="pcbi.1006664.ref049">49</xref>] from 3.4 kg at the birth time to 75 kg in the adult life. The exact numbers of these cells at time <inline-formula id="pcbi.1006664.e148"><alternatives><graphic id="pcbi.1006664.e148g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e148" xlink:type="simple"/><mml:math display="inline" id="M148"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula> are calculated based on the estimates given by Stiehl et al. [<xref ref-type="bibr" rid="pcbi.1006664.ref045">45</xref>] (in that paper’s Online Supplement, Scenario 2). Further details are available in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. <bold><xref ref-type="fig" rid="pcbi.1006664.g006">Fig 6</xref> </bold>presents the age-trajectories of model coefficients as well as those of the cell numbers in the two compartments and the flux rate of mature granulocytes into blood.</p>
</sec>
<sec id="sec020">
<title>Mutation rate, selection and age at sMDS onset in the detailed model including recurrent mutation</title>
<p>The main results of the paper are obtained by application of the comprehensive model of expansion of the <italic>CSF3R</italic> truncation mutants in the bone marrow. As described in Methods section, the model hypotheses are consistent with the age-dependence of the cell number in the CMP compartment. We disregard the influx of mutants arising in the HSC compartment, since this is a relatively minor influence compared to their number in the CMP, the increase of which is driven by their selective advantage following the G-CSF treatment. Because the Moran model with recurrent mutation has mutant fixation probability equal to 1, it applies strictly speaking only to the 70% of cases with <italic>CSF3R</italic> truncation mutation fixed at the sMDS diagnosis.</p>
<p><bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2A</xref></bold> depicts the age at which the <italic>CSF3R</italic> truncation mutants replace the normal cells in the CMP compartment. The age at replacement reaches the mean value of 13 years observed in clinical data for a range of parameter values, including mutation rate expected for human genome (ca. 10<sup>−9</sup>) and modest selection coefficient values such as 0.014 consistent with small selective advantage expected based on <bold><xref ref-type="fig" rid="pcbi.1006664.g003">Fig 3</xref> </bold>though not explicitly quantifiable. <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2B</xref></bold> depicts the values of the selection coefficient <inline-formula id="pcbi.1006664.e149"><alternatives><graphic id="pcbi.1006664.e149g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e149" xlink:type="simple"/><mml:math display="inline" id="M149"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, which for a given mutation rate lead to sMDS onset at 4, 13 and 22 years, respectively.</p>
<p>Comparison of simulations in <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref> </bold>(comprehensive model) and computations in <bold><xref ref-type="table" rid="pcbi.1006664.t001">Table 1</xref> </bold>(simplified model), leads to the conclusions summarized in <bold><xref ref-type="table" rid="pcbi.1006664.t002">Table 2</xref></bold>. Estimates of the selection coefficients needed for fixation of the <italic>CSF3R</italic> truncation mutant at ages 4, 13 and 22 years obtained from the comprehensive model are about 2–3 times higher than those based on the simplified model, with the corresponding mutation rates adjusted to those required in the simplified model. This difference stems from two facts: (1) the simplified model does not account for the change of the hematopoietic system performance with age, and (2) the comprehensive model includes recurrent mutations of <italic>CSF3R</italic> over the lifetime not only in the fetal period. In both models, the mutation rates and selection coefficients required seem to be within acceptable ranges.</p>
<p>Another graph, in <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2C</xref></bold>, depicts the corresponding mutant count at 1 year of age. We see that at mutation rates ranging over 10<sup>−9</sup>–10<sup>−7</sup>, the mutant count at birth remains in the 10<sup>1</sup>–10<sup>3</sup> range. These results confirm the proof-of-concept analysis and show that in the range of “normal” human mutation rates, the number of mutants at birth is of the order of 10<sup>2</sup>—practically undetectable even by very deep sequencing.</p>
</sec>
</sec>
</sec>
<sec id="sec021" sec-type="conclusions">
<title>Discussion</title>
<p>Here we presented a model of fixation of a <italic>CSF3R</italic> truncation mutant in the transition from an inherited neutropenia to sMDS: from the expansion phase in the prenatal hematopoietic tissues, to initiation of the G-CSF treatment, to expansion of the mutant, and to replacement of the normal bone marrow by the pre-leukemic mutants. By modifying the simple Moran model of population genetics, we provided an explanation for the evolution of sMDS in about 70% of cases in which <italic>CSF3R</italic> truncation mutant acts as an oncogenic driver. We first used a proof-of-concept two-stage model including the initial creation of the mutant clone before the selective agent G-CSF has been applied, followed by the period of selective pressure after initiation of treatment. We followed up with a more comprehensive model, which used the estimates of age-dependent productivity changes in hematopoietic stem cells, obtained based on telomere shortening estimates by the Abkowitz and Aviv groups [<xref ref-type="bibr" rid="pcbi.1006664.ref047">47</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref048">48</xref>].</p>
<p>Our model provides a real-world setting that may further illuminate principles of clonal hematopoiesis of indeterminate potential, first described as age-related clonal hematopoiesis. As recently summarized by [<xref ref-type="bibr" rid="pcbi.1006664.ref050">50</xref>], HSC clonality and association with malignancy begins with somatic genetic lesions in adult stem cells that accumulate and persist and that “given a large enough population (of HSC), every base pair in the genome will be mutated within at least one HSC”. Further, “these mutations provide the substrate for clonal selection”. The original and distinctive feature of our present model is to show that mutations occurring during the bone marrow expansion in the fetal period are likely to play a major role in creating this substrate.</p>
<p>The expected times to fixation of the <italic>CSF3R</italic> truncation mutant (4–22 years) are consistent with the timing of the sMDS onset. According to data published from the European SCN Registry data, the average age at diagnosis of SCN with sMDS and <italic>CSF3R</italic> mutation is 13 ± 9 years [<xref ref-type="bibr" rid="pcbi.1006664.ref051">51</xref>]. The 70% fixation probability requires 11–60 “initial” cells harboring the mutation. We experimentally validated our mathematical model by measuring the growth advantage of the CSF3R D715-expressing cells and found a significant growth advantage (<bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1A</xref></bold>). Further validation will require next generation sequencing of specimens from these rare patients. Qiu et al. [<xref ref-type="bibr" rid="pcbi.1006664.ref052">52</xref>] recently reported that this truncation mutation also permits granulocytic precursors to avoid apoptosis.</p>
<p>Our comprehensive model is based on the hypothesis that the rate of cell division after birth, when the rapid expansion of bone marrow slows down, is still very high. Hence, acquisition of new mutants during that phase is still substantial. However, selection is the force that leads the mutant-receptor cells to dominate. This also means that supply of new mutants in the expansion phase might not be necessary for the disease to emerge. However, it is likely that proliferation slows down by one or two orders of magnitude, depending on exact characteristics of subtypes of stem cells. Then in order to fit the data, somewhat higher selection coefficients are needed. In that case, the comprehensive model will behave approximately as the “proof of the concept” model, i.e. most of the mutant are supplied in the marrow expansion stage.</p>
<p>An alternative hypothesis states that an inherited neutropenia induces a maladaptive increase in replicative stress and higher mutation rate in HSC that contributes to transformation to sMDS/AML [<xref ref-type="bibr" rid="pcbi.1006664.ref053">53</xref>]. However, measurements of the mutation burden in individual hematopoietic stem/progenitor cells (HSPCs) from SCN patients failed to support that. CD34<sup>+</sup>CD38<sup>-</sup> cells were sorted from blood or bone marrow samples and cultured for 3–4 weeks on irradiated stromal feeder cells. The exomes of the expanded HSPC clones were sequenced with unsorted hematopoietic cells from the same patient served as a normal control. The average number of somatic mutations per exome was 3.6 ± 1.2 for SCN, compared to 3.9 ± 0.4 for the healthy controls. Those patient-derived findings support our model. Our conclusions require that the mutation rate per site per cell division equals about 10<sup>−9</sup>, which is consistent with normal mutation rate in human genome.</p>
<p>This latter issue warrants discussion since the somatic mutation rate in humans is about two orders of magnitude higher than the germline mutation rate, as suggested by [<xref ref-type="bibr" rid="pcbi.1006664.ref054">54</xref>]. However, a recent paper by Milholland et al. [<xref ref-type="bibr" rid="pcbi.1006664.ref055">55</xref>], argues that this former (somatic rate) is of the order of 10<sup>−9</sup> per base per mitosis, while the former (germline rate) is of the order of 10<sup>−11</sup> per base per mitosis (<bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1B</xref></bold> in that paper). Moreover, as seen in our <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref></bold>, using the 10<sup>−7</sup> mutation rate [<xref ref-type="bibr" rid="pcbi.1006664.ref054">54</xref>] would only slightly change our conclusions.</p>
<p>Two other mechanisms drive the expansion of the CSF3R truncation mutants, (i) the initial CSF3R truncation mutant cell clones arising in the expansion phase of fetal hematopoietic bone marrow and (ii) competitive advantage of the CSF3R truncation mutant harboring cells at later ages, hypothetically due to increased G-CSF pressure. “Mutator phenotype” does not need to be invoked in the SCN progression to sMDS.</p>
<p>A characteristic feature of human cancers is their wide heterogeneity with respect to extent of involvement, genotype, and rate of progression and spread [<xref ref-type="bibr" rid="pcbi.1006664.ref056">56</xref>]. This variability contrasts markedly to induced animal tumors, which grow at a relatively uniform rate. sMDS/AML secondary to SCN is not an exception, with onset varying from 1 to 38 years of age. Previously, we constructed a stochastic model of the SNC→sMDS→sAML transition based on stochastic events [<xref ref-type="bibr" rid="pcbi.1006664.ref009">9</xref>]. It considered each new mutation to provide more selective advantage to the arising clone. This linear structure of mutation conferred desirable simplicity to modeling but was not necessarily realistic. In the framework of multitype branching processes and special processes such as Griffiths and Pakes branching infinite allele model [<xref ref-type="bibr" rid="pcbi.1006664.ref057">57</xref>, <xref ref-type="bibr" rid="pcbi.1006664.ref058">58</xref>], more complicated scenarios might be contemplated. Interestingly, the model of ref. [<xref ref-type="bibr" rid="pcbi.1006664.ref009">9</xref>] suggests that the spread in the age of onset of sAML is not due solely to stochastic nature of clone transitions, but requires a large variability in proliferative potential from one affected individual to another.</p>
<p>Similar effect can be predicted in the Moran process. According to [<xref ref-type="bibr" rid="pcbi.1006664.ref038">38</xref>], the time course of the Moran process under mutant selective advantage can be split into three periods: (1) relatively long period from small number of mutant cells to a threshold, followed by (2) a much shorter period from the threshold to near-fixation of the mutant, and (3) a relatively long period to complete fixation. Accordingly, once the mutant count exceeds certain threshold, the process accelerates. This results in the spread of times to fixation depending at least as strongly on the selection coefficient as on the “intrinsic” randomness. This justifies the approach we took in this study, to concentrate on the effects of the selection coefficient. In addition, determination of the threshold may help establish a target for monitoring the progress of the disease. Gaining more insight will require a further study.</p>
<p>While our model advances the understanding of multistep progression to cancer with a real-world condition and application to the clinic, other factors could be incorporated. These include: a correlation between G-CSF dosage for neutrophil recovery in SCN patients and the risk of malignant transformation and acquisition of an additional mutation, such as <italic>RUNX1</italic>, in the evolution to sAML.</p>
<p>In the current report, we focus on a single aspect of the SCN-related leukemogenesis: expansion of <italic>CSF3R</italic> truncation mutant cells leading to the sMDS transformation. The model we present here provides potentially testable hypotheses (i) the <italic>CSF3R</italic> truncation mutants are present in <inline-formula id="pcbi.1006664.e150"><alternatives><graphic id="pcbi.1006664.e150g" mimetype="image" position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1006664.e150" xlink:type="simple"/><mml:math display="inline" id="M150"><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> cells before G-CSF treatment is applied and (ii) a slight selective advantage of the <italic>CSF3R</italic> truncation mutant-harboring cells under G-CSF pressure is sufficient to lead to their expansion. The second hypothesis seems to be consistent with findings in ref [<xref ref-type="bibr" rid="pcbi.1006664.ref053">53</xref>]. Current dogma holds that clonal dynamics in relation to the development of sMDS/AML are highly heterogeneous and unpredictable. Our model supports the clinical value of more accurate disease surveillance with next generation sequencing and better timing of therapeutic interventions, such as stem cell transplantation.</p>
</sec>
<sec id="sec022">
<title>Supporting information</title>
<supplementary-material id="pcbi.1006664.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1006664.s001" xlink:type="simple">
<label>S1 Appendix</label>
<caption>
<title>Supporting methods.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pcbi.1006664.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McFarland</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Mirny</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Korolev</surname> <given-names>KS</given-names></name>. <article-title>Tug-of-war between driver and passenger mutations in cancer and other adaptive processes</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>(<issue>42</issue>):<fpage>15138</fpage>–<lpage>43</lpage>. Epub 2014/10/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1404341111" xlink:type="simple">10.1073/pnas.1404341111</ext-link></comment> <object-id pub-id-type="pmid">25277973</object-id>; PubMed Central PMCID: PMCPMC4210325.</mixed-citation></ref>
<ref id="pcbi.1006664.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McFarland</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Yaglom</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Wojtkowiak</surname> <given-names>JW</given-names></name>, <name name-style="western"><surname>Scott</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Morse</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Sherman</surname> <given-names>MY</given-names></name>, <etal>et al</etal>. <article-title>The Damaging Effect of Passenger Mutations on Cancer Progression</article-title>. <source>Cancer Res</source>. <year>2017</year>;<volume>77</volume>(<issue>18</issue>):<fpage>4763</fpage>–<lpage>72</lpage>. Epub 2017/05/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-15-3283-T" xlink:type="simple">10.1158/0008-5472.CAN-15-3283-T</ext-link></comment> <object-id pub-id-type="pmid">28536279</object-id>; PubMed Central PMCID: PMCPMC5639691.</mixed-citation></ref>
<ref id="pcbi.1006664.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Davis</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Navin</surname> <given-names>N</given-names></name>. <article-title>Tumor evolution: Linear, branching, neutral or punctuated?</article-title> <source>Biochim Biophys Acta</source>. <year>2017</year>;<volume>1867</volume>(<issue>2</issue>):<fpage>151</fpage>–<lpage>61</lpage>. Epub 2017/01/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbcan.2017.01.003" xlink:type="simple">10.1016/j.bbcan.2017.01.003</ext-link></comment> <object-id pub-id-type="pmid">28110020</object-id>; PubMed Central PMCID: PMCPMC5558210.</mixed-citation></ref>
<ref id="pcbi.1006664.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gao</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>McDonald</surname> <given-names>TO</given-names></name>, <name name-style="western"><surname>Sei</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Shi</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Punctuated copy number evolution and clonal stasis in triple-negative breast cancer</article-title>. <source>Nat Genet</source>. <year>2016</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1119</fpage>–<lpage>30</lpage>. Epub 2016/08/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng.3641" xlink:type="simple">10.1038/ng.3641</ext-link></comment> <object-id pub-id-type="pmid">27526321</object-id>; PubMed Central PMCID: PMCPMC5042845.</mixed-citation></ref>
<ref id="pcbi.1006664.ref005"><label>5</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Durrett</surname> <given-names>R</given-names></name>. <source>Branching process models of cancer</source>. <name name-style="western"><surname>Golubitsky</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Reed</surname> <given-names>M.</given-names></name>, editor: <collab>Springer</collab>, <publisher-loc>Cham</publisher-loc>; <year>2015</year>. <fpage>63</fpage> p.</mixed-citation></ref>
<ref id="pcbi.1006664.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomasetti</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Durrett</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lambert</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Parmigiani</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Zauber</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Role of stem-cell divisions in cancer risk</article-title>. <source>Nature</source>. <year>2017</year>;<volume>548</volume>(<issue>7666</issue>):<fpage>E13</fpage>–<lpage>E4</lpage>. Epub 2017/08/11. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature23302" xlink:type="simple">10.1038/nature23302</ext-link></comment> <object-id pub-id-type="pmid">28796214</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref007"><label>7</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Nowak</surname> <given-names>MA</given-names></name>. <chapter-title>Evolutionary dynamics</chapter-title>. <source>Exploring the Equations of Life</source>: <publisher-name>Harvard University Press</publisher-name>; <year>2006</year>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref008"><label>8</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Axelrod</surname> <given-names>DE</given-names></name>. <source>Branching Processes in Biology</source>: <publisher-name>Springer</publisher-name> <year>2015</year>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Corey</surname> <given-names>S</given-names></name>. <article-title>Stochastic Hypothesis of Transition from Inborn Neutropenia to AML: Interactions of Cell Population Dynamics and Population Genetics</article-title>. <source>Frontiers in oncology</source>. <year>2013</year>;<volume>3</volume>:<fpage>89</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fonc.2013.00089" xlink:type="simple">10.3389/fonc.2013.00089</ext-link></comment> <object-id pub-id-type="pmid">23641360</object-id>; PubMed Central PMCID: PMC3638131.</mixed-citation></ref>
<ref id="pcbi.1006664.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Whichard</surname> <given-names>ZL</given-names></name>, <name name-style="western"><surname>Sarkar</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Corey</surname> <given-names>SJ</given-names></name>. <article-title>Hematopoiesis and its disorders: a systems biology approach</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>(<issue>12</issue>):<fpage>2339</fpage>–<lpage>47</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2009-08-215798" xlink:type="simple">10.1182/blood-2009-08-215798</ext-link></comment> <object-id pub-id-type="pmid">20103779</object-id>; PubMed Central PMCID: PMCPMC2845894.</mixed-citation></ref>
<ref id="pcbi.1006664.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matatall</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Jeong</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sun</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Mo</surname> <given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Chronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>17</volume>(<issue>10</issue>):<fpage>2584</fpage>–<lpage>95</lpage>. Epub 2016/12/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.celrep.2016.11.031" xlink:type="simple">10.1016/j.celrep.2016.11.031</ext-link></comment> <object-id pub-id-type="pmid">27926863</object-id>; PubMed Central PMCID: PMCPMC5161248.</mixed-citation></ref>
<ref id="pcbi.1006664.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomasetti</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Vogelstein</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Parmigiani</surname> <given-names>G</given-names></name>. <article-title>Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>(<issue>6</issue>):<fpage>1999</fpage>–<lpage>2004</lpage>. Epub 2013/01/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1221068110" xlink:type="simple">10.1073/pnas.1221068110</ext-link></comment> <object-id pub-id-type="pmid">23345422</object-id>; PubMed Central PMCID: PMCPMC3568331.</mixed-citation></ref>
<ref id="pcbi.1006664.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Horwitz</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Corey</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Grimes</surname> <given-names>HL</given-names></name>, <name name-style="western"><surname>Tidwell</surname> <given-names>T</given-names></name>. <article-title>ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology</article-title>. <source>Hematology/oncology clinics of North America</source>. <year>2013</year>;<volume>27</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>41</lpage>, vii. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.hoc.2012.10.004" xlink:type="simple">10.1016/j.hoc.2012.10.004</ext-link></comment> <object-id pub-id-type="pmid">23351986</object-id>; PubMed Central PMCID: PMC3559001.</mixed-citation></ref>
<ref id="pcbi.1006664.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mehta</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Malandra</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Corey</surname> <given-names>SJ</given-names></name>. <article-title>G-CSF and GM-CSF in Neutropenia</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>195</volume>(<issue>4</issue>):<fpage>1341</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4049/jimmunol.1500861" xlink:type="simple">10.4049/jimmunol.1500861</ext-link></comment> <object-id pub-id-type="pmid">26254266</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Donadieu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Leblanc</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Bader Meunier</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Barkaoui</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fenneteau</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Bertrand</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group</article-title>. <source>Haematologica</source>. <year>2005</year>;<volume>90</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>53</lpage>. Epub 2005/01/12. <object-id pub-id-type="pmid">15642668</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rosenberg</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Alter</surname> <given-names>BP</given-names></name>, <name name-style="western"><surname>Bolyard</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Bonilla</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Boxer</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Cham</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy</article-title>. <source>Blood</source>. <year>2006</year>;<volume>107</volume>(<issue>12</issue>):<fpage>4628</fpage>–<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2005-11-4370" xlink:type="simple">10.1182/blood-2005-11-4370</ext-link></comment> <object-id pub-id-type="pmid">16497969</object-id>; PubMed Central PMCID: PMCPMC1895804.</mixed-citation></ref>
<ref id="pcbi.1006664.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kojima</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tsuchida</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Matsuyama</surname> <given-names>T</given-names></name>. <article-title>Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>326</volume>(<issue>19</issue>):<fpage>1294</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM199205073261917" xlink:type="simple">10.1056/NEJM199205073261917</ext-link></comment> <object-id pub-id-type="pmid">1373226</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hershman</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Neugut</surname> <given-names>AI</given-names></name>, <name name-style="western"><surname>Jacobson</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Tsai</surname> <given-names>WY</given-names></name>, <name name-style="western"><surname>McBride</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy</article-title>. <source>J Natl Cancer Inst</source>. <year>2007</year>;<volume>99</volume>(<issue>3</issue>):<fpage>196</fpage>–<lpage>205</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/jnci/djk028" xlink:type="simple">10.1093/jnci/djk028</ext-link></comment> <object-id pub-id-type="pmid">17284714</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beekman</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Touw</surname> <given-names>IP</given-names></name>. <article-title>G-CSF and its receptor in myeloid malignancy</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>(<issue>25</issue>):<fpage>5131</fpage>–<lpage>6</lpage>. Epub 2010/03/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2010-01-234120" xlink:type="simple">10.1182/blood-2010-01-234120</ext-link></comment> <object-id pub-id-type="pmid">20237318</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ehlers</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Herbst</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Zimmermann</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Scharn</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Germeshausen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>von Neuhoff</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2010</year>;<volume>28</volume>(<issue>15</issue>):<fpage>2591</fpage>–<lpage>7</lpage>. Epub 2010/04/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1200/JCO.2009.25.9010" xlink:type="simple">10.1200/JCO.2009.25.9010</ext-link></comment> <object-id pub-id-type="pmid">20406937</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Touw</surname> <given-names>IP</given-names></name>, <name name-style="western"><surname>Beekman</surname> <given-names>R</given-names></name>. <article-title>Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R</article-title>. <source>Haematologica</source>. <year>2013</year>;<volume>98</volume>(<issue>10</issue>):<fpage>1490</fpage>–<lpage>2</lpage>. Epub 2013/10/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2013.090571" xlink:type="simple">10.3324/haematol.2013.090571</ext-link></comment> <object-id pub-id-type="pmid">24091926</object-id>; PubMed Central PMCID: PMCPMC3789450.</mixed-citation></ref>
<ref id="pcbi.1006664.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dong</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Brynes</surname> <given-names>RK</given-names></name>, <name name-style="western"><surname>Tidow</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Welte</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Lowenberg</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Touw</surname> <given-names>IP</given-names></name>. <article-title>Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>(<issue>8</issue>):<fpage>487</fpage>–<lpage>93</lpage>. Epub 1995/08/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM199508243330804" xlink:type="simple">10.1056/NEJM199508243330804</ext-link></comment> <object-id pub-id-type="pmid">7542747</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Germeshausen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Skokowa</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ballmaier</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Zeidler</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Welte</surname> <given-names>K</given-names></name>. <article-title>G-CSF receptor mutations in patients with congenital neutropenia</article-title>. <source>Curr Opin Hematol</source>. <year>2008</year>;<volume>15</volume>(<issue>4</issue>):<fpage>332</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MOH.0b013e328303b9f6" xlink:type="simple">10.1097/MOH.0b013e328303b9f6</ext-link></comment> <object-id pub-id-type="pmid">18536571</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Beekman</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Valkhof</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Sanders</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>van Strien</surname> <given-names>PMH</given-names></name>, <name name-style="western"><surname>Haanstra</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Broeders</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <source>Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia</source><year>2012</year> 2012-05-31 00:00:00. <fpage>5071</fpage>–<lpage>7</lpage> p.</mixed-citation></ref>
<ref id="pcbi.1006664.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vogelstein</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Fearon</surname> <given-names>ER</given-names></name>, <name name-style="western"><surname>Hamilton</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Kern</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Preisinger</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Leppert</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Genetic alterations during colorectal-tumor development</article-title>. <source>N Engl J Med</source>. <year>1988</year>;<volume>319</volume>(<issue>9</issue>):<fpage>525</fpage>–<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM198809013190901" xlink:type="simple">10.1056/NEJM198809013190901</ext-link></comment> <object-id pub-id-type="pmid">2841597</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yates</surname> <given-names>LR</given-names></name>, <name name-style="western"><surname>Campbell</surname> <given-names>PJ</given-names></name>. <article-title>Evolution of the cancer genome</article-title>. <source>Nat Rev Genet</source>. <year>2012</year>;<volume>13</volume>(<issue>11</issue>):<fpage>795</fpage>–<lpage>806</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrg3317" xlink:type="simple">10.1038/nrg3317</ext-link></comment> <object-id pub-id-type="pmid">23044827</object-id>; PubMed Central PMCID: PMCPMC3666082.</mixed-citation></ref>
<ref id="pcbi.1006664.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ortmann</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Kent</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Nangalia</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Silber</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wedge</surname> <given-names>DC</given-names></name>, <name name-style="western"><surname>Grinfeld</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Effect of mutation order on myeloproliferative neoplasms</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>7</issue>):<fpage>601</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMoa1412098" xlink:type="simple">10.1056/NEJMoa1412098</ext-link></comment> <object-id pub-id-type="pmid">25671252</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martincorena</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Roshan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gerstung</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ellis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Van Loo</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>McLaren</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin</article-title>. <source>Science</source>. <year>2015</year>;<volume>348</volume>(<issue>6237</issue>):<fpage>880</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.aaa6806" xlink:type="simple">10.1126/science.aaa6806</ext-link></comment> <object-id pub-id-type="pmid">25999502</object-id>; PubMed Central PMCID: PMCPMC4471149.</mixed-citation></ref>
<ref id="pcbi.1006664.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McCulloch</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Till</surname> <given-names>JE</given-names></name>. <article-title>The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice</article-title>. <source>Radiation research</source>. <year>1960</year>;<volume>13</volume>:<fpage>115</fpage>–<lpage>25</lpage>. <object-id pub-id-type="pmid">13858509</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Groopman</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Molina</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Scadden</surname> <given-names>DT</given-names></name>. <article-title>Hematopoietic growth factors. Biology and clinical applications</article-title>. <source>N Engl J Med</source>. <year>1989</year>;<volume>321</volume>(<issue>21</issue>):<fpage>1449</fpage>–<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM198911233212106" xlink:type="simple">10.1056/NEJM198911233212106</ext-link></comment> <object-id pub-id-type="pmid">2682244</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaushansky</surname> <given-names>K</given-names></name>. <article-title>Lineage-specific hematopoietic growth factors</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>19</issue>):<fpage>2034</fpage>–<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMra052706" xlink:type="simple">10.1056/NEJMra052706</ext-link></comment> <object-id pub-id-type="pmid">16687716</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rieger</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Hoppe</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Smejkal</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Eitelhuber</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Schroeder</surname> <given-names>T</given-names></name>. <article-title>Hematopoietic cytokines can instruct lineage choice</article-title>. <source>Science</source>. <year>2009</year>;<volume>325</volume>(<issue>5937</issue>):<fpage>217</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1171461" xlink:type="simple">10.1126/science.1171461</ext-link></comment> <object-id pub-id-type="pmid">19590005</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref033"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">FlowJo L. FlowJo, LLC, 2013–2018; [cited 2018]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo" xlink:type="simple">https://www.flowjo.com/solutions/flowjo</ext-link>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>. <article-title>Cellular population dynamics. I. Model construction and reformulation</article-title>. <source>Mathematical Biosciences</source>. <year>1980</year>;<volume>48</volume>(<issue>3/4</issue>):<fpage>211</fpage>–<lpage>24</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>. <article-title>Cellular population dynamics. II. Investigation of solutions</article-title>. <source>Mathematical Biosciences</source>. <year>1980</year>;<volume>48</volume>(<issue>3/4</issue>):<fpage>225</fpage>–<lpage>39</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stute</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Santana</surname> <given-names>VM</given-names></name>, <name name-style="western"><surname>Rodman</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Schell</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Ihle</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>WE</given-names></name>. <article-title>Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children</article-title>. <source>Blood</source>. <year>1992</year>;<volume>79</volume>(<issue>11</issue>):<fpage>2849</fpage>–<lpage>54</lpage>. Epub 1992/06/01. <object-id pub-id-type="pmid">1375115</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref037"><label>37</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Alon</surname> <given-names>U</given-names></name>. <source>An Introduction to Systems Biology: Design Principles of Biological Circuits</source> <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Chapman &amp; Hall</publisher-name>; <year>2007</year>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref038"><label>38</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Durrett</surname> <given-names>R</given-names></name>. <source>Probability Models for DNA Sequence Evolution</source>: <publisher-name>Springer</publisher-name>; <year>2008</year>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Donadieu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Beaupain</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Rety-Jacob</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Nove-Josserand</surname> <given-names>R</given-names></name>. <article-title>Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim</article-title>. <source>Haematologica</source>. <year>2009</year>;<volume>94</volume>(<issue>8</issue>):<fpage>1175</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3324/haematol.2008.005330" xlink:type="simple">10.3324/haematol.2008.005330</ext-link></comment> <object-id pub-id-type="pmid">19644144</object-id>; PubMed Central PMCID: PMCPMC2719042.</mixed-citation></ref>
<ref id="pcbi.1006664.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dong</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>van Buitenen</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pouwels</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hoefsloot</surname> <given-names>LH</given-names></name>, <name name-style="western"><surname>Lowenberg</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Touw</surname> <given-names>IP</given-names></name>. <article-title>Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation</article-title>. <source>Mol Cell Biol</source>. <year>1993</year>;<volume>13</volume>(<issue>12</issue>):<fpage>7774</fpage>–<lpage>81</lpage>. Epub 1993/12/01. <object-id pub-id-type="pmid">8246993</object-id>; PubMed Central PMCID: PMCPMC364849.</mixed-citation></ref>
<ref id="pcbi.1006664.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dowling</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Levy</surname> <given-names>O</given-names></name>. <article-title>Ontogeny of early life immunity</article-title>. <source>Trends Immunol</source>. <year>2014</year>;<volume>35</volume>(<issue>7</issue>):<fpage>299</fpage>–<lpage>310</lpage>. Epub 2014/06/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.it.2014.04.007" xlink:type="simple">10.1016/j.it.2014.04.007</ext-link></comment> <object-id pub-id-type="pmid">24880460</object-id>; PubMed Central PMCID: PMCPMC4109609.</mixed-citation></ref>
<ref id="pcbi.1006664.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Orkin</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Zon</surname> <given-names>LI</given-names></name>. <article-title>Hematopoiesis: an evolving paradigm for stem cell biology</article-title>. <source>Cell</source>. <year>2008</year>;<volume>132</volume>(<issue>4</issue>):<fpage>631</fpage>–<lpage>44</lpage>. Epub 2008/02/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2008.01.025" xlink:type="simple">10.1016/j.cell.2008.01.025</ext-link></comment> <object-id pub-id-type="pmid">18295580</object-id>; PubMed Central PMCID: PMCPMC2628169.</mixed-citation></ref>
<ref id="pcbi.1006664.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goldie</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Coldman</surname> <given-names>AJ</given-names></name>. <article-title>A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate</article-title>. <source>Cancer Treat Rep</source>. <year>1979</year>;<volume>63</volume>(<issue>11–12</issue>):<fpage>1727</fpage>–<lpage>33</lpage>. <object-id pub-id-type="pmid">526911</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goldie</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Coldman</surname> <given-names>AJ</given-names></name>. <article-title>Genetic instability in the development of drug resistance</article-title>. <source>Semin Oncol</source>. <year>1985</year>;<volume>12</volume>(<issue>3</issue>):<fpage>222</fpage>–<lpage>30</lpage>. <object-id pub-id-type="pmid">4048965</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stiehl</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Ho</surname> <given-names>AD</given-names></name>, <name name-style="western"><surname>Marciniak-Czochra</surname> <given-names>A</given-names></name>. <article-title>The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling</article-title>. <source>Bone Marrow Transplant</source>. <year>2014</year>;<volume>49</volume>(<issue>1</issue>):<fpage>30</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/bmt.2013.138" xlink:type="simple">10.1038/bmt.2013.138</ext-link></comment> <object-id pub-id-type="pmid">24056742</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arino</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>. <article-title>Stability Analysis of Models of Cell Production Systems</article-title>. <source>Math Modelling</source>. <year>1986</year>;<volume>7</volume>(<issue>9–12</issue>):<fpage>1269</fpage>–<lpage>300</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/0270-0255(86)90081-3" xlink:type="simple">10.1016/0270-0255(86)90081-3</ext-link></comment> PubMed PMID: WOS:A1986F488000009.</mixed-citation></ref>
<ref id="pcbi.1006664.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shepherd</surname> <given-names>BE</given-names></name>, <name name-style="western"><surname>Guttorp</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lansdorp</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Abkowitz</surname> <given-names>JL</given-names></name>. <article-title>Estimating human hematopoietic stem cell kinetics using granulocyte telomere lengths</article-title>. <source>Exp Hematol</source>. <year>2004</year>;<volume>32</volume>(<issue>11</issue>):<fpage>1040</fpage>–<lpage>50</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.exphem.2004.07.023" xlink:type="simple">10.1016/j.exphem.2004.07.023</ext-link></comment> <object-id pub-id-type="pmid">15539081</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sidorov</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kimura</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yashin</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Aviv</surname> <given-names>A</given-names></name>. <article-title>Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth</article-title>. <source>Exp Hematol</source>. <year>2009</year>;<volume>37</volume>(<issue>4</issue>):<fpage>514</fpage>–<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.exphem.2008.11.009" xlink:type="simple">10.1016/j.exphem.2008.11.009</ext-link></comment> <object-id pub-id-type="pmid">19216021</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>So</surname> <given-names>TY</given-names></name>, <name name-style="western"><surname>Farrington</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Absher</surname> <given-names>RK</given-names></name>. <article-title>Evaluation of the accuracy of different methods used to estimate weights in the pediatric population</article-title>. <source>Pediatrics</source>. <year>2009</year>;<volume>123</volume>(<issue>6</issue>):<fpage>e1045</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1542/peds.2008-1968" xlink:type="simple">10.1542/peds.2008-1968</ext-link></comment> <object-id pub-id-type="pmid">19482737</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jan</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Ebert</surname> <given-names>BL</given-names></name>, <name name-style="western"><surname>Jaiswal</surname> <given-names>S</given-names></name>. <article-title>Clonal hematopoiesis</article-title>. <source>Semin Hematol</source>. <year>2017</year>;<volume>54</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>50</lpage>. Epub 2017/01/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.seminhematol.2016.10.002" xlink:type="simple">10.1053/j.seminhematol.2016.10.002</ext-link></comment> <object-id pub-id-type="pmid">28088988</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Skokowa</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Steinemann</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Katsman-Kuipers</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Zeidler</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Klimenkova</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Klimiankou</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Cooperativity of RUNX1 and CSF3R mutations in the development of leukemia in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis</article-title>. <source>Blood</source>. <year>2014</year>. Epub 2014/02/14. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2013-11-538025" xlink:type="simple">10.1182/blood-2013-11-538025</ext-link></comment> <object-id pub-id-type="pmid">24523240</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qiu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>F</given-names></name>. A <article-title>Truncated Granulocyte Colony-stimulating Factor Receptor (G-CSFR) Inhibits Apoptosis Induced by Neutrophil Elastase G185R Mutant: implication for understanding CSF3R gene mutatiopns in severe congenital neutropenia</article-title>. <source>J Biol Chem</source>. <year>2017</year>;<volume>292</volume>(<issue>8</issue>):<fpage>3496</fpage>–<lpage>505</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M116.755157" xlink:type="simple">10.1074/jbc.M116.755157</ext-link></comment> <object-id pub-id-type="pmid">28073911</object-id>; PubMed Central PMCID: PMCPMC5336180.</mixed-citation></ref>
<ref id="pcbi.1006664.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xia</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Baty</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ramesh</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jotte</surname> <given-names>MRM</given-names></name>, <name name-style="western"><surname>Fulton</surname> <given-names>RS</given-names></name>, <etal>et al</etal>. <article-title>Somatic mutations and clonal hematopoiesis in congenital neutropenia</article-title>. <source>Blood</source>. <year>2017</year>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2017-08-801985" xlink:type="simple">10.1182/blood-2017-08-801985</ext-link></comment> <object-id pub-id-type="pmid">29092827</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Araten</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Golde</surname> <given-names>DW</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>RH</given-names></name>, <name name-style="western"><surname>Thaler</surname> <given-names>HT</given-names></name>, <name name-style="western"><surname>Gargiulo</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Notaro</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>A quantitative measurement of the human somatic mutation rate</article-title>. <source>Cancer Res</source>. <year>2005</year>;<volume>65</volume>(<issue>18</issue>):<fpage>8111</fpage>–<lpage>7</lpage>. Epub 2005/09/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1158/0008-5472.CAN-04-1198" xlink:type="simple">10.1158/0008-5472.CAN-04-1198</ext-link></comment> <object-id pub-id-type="pmid">16166284</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Milholland</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Hao</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Suh</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Vijg</surname> <given-names>J</given-names></name>. <article-title>Differences between germline and somatic mutation rates in humans and mice</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>:<fpage>15183</fpage>. Epub 2017/05/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncomms15183" xlink:type="simple">10.1038/ncomms15183</ext-link></comment> <object-id pub-id-type="pmid">28485371</object-id>; PubMed Central PMCID: PMCPMC5436103.</mixed-citation></ref>
<ref id="pcbi.1006664.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hanahan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Weinberg</surname> <given-names>RA</given-names></name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>;<volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2011.02.013" xlink:type="simple">10.1016/j.cell.2011.02.013</ext-link></comment> <object-id pub-id-type="pmid">21376230</object-id>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Griffiths</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Pakes</surname> <given-names>AG</given-names></name>. <article-title>An infinite alleles version of the simple branching process</article-title>. <source>Adv Appl Prob</source>. <year>1988</year>;<volume>20</volume>:<fpage>489</fpage>–<lpage>524</lpage>.</mixed-citation></ref>
<ref id="pcbi.1006664.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McDonald</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kimmel</surname> <given-names>M</given-names></name>. <article-title>A multitype infinite-allele branching process with applications to cancer evolution</article-title>. <source>Journal of Applied Probability</source> <year>2015</year>;<volume>52</volume>(<issue>3</issue>):<fpage>864</fpage>–<lpage>76</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>